

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 9/12, A61K 38/45, C07K 16/18, 16/40		A1	(11) International Publication Number: WO 00/70028 (43) International Publication Date: 23 November 2000 (23.11.00)
(21) International Application Number: PCT/AU00/00457 (22) International Filing Date: 12 May 2000 (12.05.00)		(74) Agents: SLATTERY, John, Michael et al.; Davies Collison Cave, 1 Little Collins Street, Melbourne, Victoria 3000 (AU).	
(30) Priority Data: PQ 0339 13 May 1999 (13.05.99) AU PQ 1504 8 July 1999 (08.07.99) AU		(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(71) Applicant (for all designated States except US): JOHNSON & JOHNSON RESEARCH PTY. LIMITED [AU/AU]; 1 Central Avenue, Australian Technology Park, Everleigh, NSW 1430 (AU).		Published With international search report.	
(72) Inventors; and (75) Inventors/Applicants (for US only): PITSON, Stuart, Maxwell [AU/AU]; 1B Threlfall Avenue, Norwood, South Australia 5067 (AU). WATTENBERG, Brian, Wolff [US/AU]; 137 Sheoak Road, Belair, South Australia 5052 (AU). XIA, Pu [CN/AU]; 97 Shakespeare Avenue, Magill, South Australia 5072 (AU). D'ANDREA, Richard, James [AU/AU]; 54 Allendale Grove, Stonyfell, South Australia 5066 (AU). GAMBLE, Jennifer, Ruth [AU/AU]; 8 Branch Road, Stirling, South Australia 5152 (AU). VADAS, Mathew, Alexander [AU/AU]; 8 Branch Road, Stirling, South Australia 5152 (AU).			

(54) Title: SPHINGOSINE KINASE ENZYME

(57) Abstract

The present invention relates generally to novel protein molecules and to derivatives, analogues, chemical equivalents and mimetics thereof capable of modulating cellular activity and, in particular, modulating cellular activity via the modulation of signal transduction. More particularly, the present invention relates to human sphingosine kinase and to derivatives, analogues, chemical equivalents and mimetics thereof. The present invention also contemplates genetic sequences encoding said protein molecules and derivatives, analogues, chemical equivalents and mimetics thereof. The molecules of the present invention are useful in a range of therapeutic, prophylactic and diagnostic applications.

[illegible]

195	G T F L R L A A L R T Y R G R L A Y L P V G R V G	219
601	G G C A C T T C C T G C T G G C A G C C T T G G C A C T A C C C G C G C A C T G C C T T A C C T C C C T G T A G G A A G A G T G G T	675
270	S K T P A S P V G Q Q Q P V D A H L V P L E E P	244
676	T C C A A G A C A C T G C C T C C C C C G T T G T G T C A G C A G G C C C G T A G A T G C A C A C T T G G C C A C T G G A G A G C C A	750
245	V P S H N T V V P V D E D F V L L L A L L S H L G	269
751	G T G C C T T C A C T A G C A A T G G T G C C C A G C A G A G A C T T G T C T A G T C C T G G C A C T G C T G C A C T G C C A C T G G G C	825
270	S E N F A A P H G R C A A G V M H L F Y V R A G V	294
826	A G T G A G A T T G T T G C A C C A T G G C C C G C T G T G C A C T G G C C A T G C A T G T T C T A C G T C G C G G C G G A G T G	900
295	S R A M L L R L F L A H E K G R H N E S C P Y L	919
901	T C T G T G C C A T G C T G C G C C C T C T C T C T G C C C A T G G A A A G G C A G G C A T A T G A G A T G A A T G C C C C T A C T T G	975
270	V Y P V V A P R L E P K D G K H F A V D G E L	344
976	G T A T A T G T C C C C T G T G C C C T C C C C T T G G A G C C C A A G G A T G G G A A A G G T A T T G C A G T A T G G G G A A T T G	1050
345	M V S E A V C Q Q G V H P N V S G C V E P P	369
1051	A T T G T A A G C A G C G T G C A G G C G A G T G C A C C C A A A C T A C T T C T G A T G G T A C C G G T T G C G T G A G C C C C C G	1125
270	S T G A A G C C C P P P E E P L	384
1126	C C C A G C T G G A A G C C C A G C A G A T G C C A C G C C A G A A G A G C C C T A T g s	1173

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

- 1 -

SPHINGOSINE KINASE ENZYME

FIELD OF THE INVENTION

5 The present invention relates generally to novel protein molecules and to derivatives, analogues, chemical equivalents and mimetics thereof capable of modulating cellular activity and, in particular, modulating cellular activity via the modulation of signal transduction. More particularly, the present invention relates to human sphingosine kinase and to derivatives, analogues, chemical equivalents and mimetics thereof. The present invention
10 also contemplates genetic sequences encoding said protein molecules and derivatives, analogues, chemical equivalents and mimetics thereof. The molecules of the present invention are useful in a range of therapeutic, prophylactic and diagnostic applications.

BACKGROUND OF THE INVENTION

15

Bibliographic details of the publications referred to by author in this specification are collected alphabetically at the end of the description.

Sphingosine kinase is a key regulatory enzyme in a variety of cellular responses. Its activity
20 can affect inflammation, apoptosis and cell proliferation, and thus it is an important target for therapeutic intervention.

Sphingosine-1-phosphate is known to be an important second messenger in signal transduction (Meyer *et al.*, 1997). It is mitogenic in various cell types (Alessenko, 1998;
25 Spiegel *et al.*, 1998) and appears to trigger a diverse range of important regulatory pathways including; prevention of ceramide-induced apoptosis (Culliver *et al.*, 1996), mobilisation of intracellular calcium by an IP₃-independant pathway, stimulation of DNA synthesis, activation of mitogen-activated protein (MAP) kinase pathway, activation of phospholipase D, and regulation of cell motility (for reviews see Meyer *et al.*, 1997; Spiegel *et al.*, 1998;
30 Igarashi., 1997).

- 2 -

Recent studies (Xia *et al.*, 1998) have shown that sphingosine-1-phosphate is an obligatory signalling intermediate in the inflammatory response of vascular endothelial cells to tumour necrosis factor- α (TNF α). In spite of its obvious importance, very little is known of the mechanisms that control cellular sphingosine-1-phosphate levels. It is known that

5 sphingosine-1-phosphate levels in the cell are mediated largely by its formation from sphingosine by sphingosine kinase, and to a lesser extent by its degradation by endoplasmic reticulum-associated sphingosine-1-phosphate lyase and sphingosine-1-phosphate phosphatase (Spiegel *et al.*, 1998). Basal levels of sphingosine-1-phosphate in the cell are generally low, but can increase rapidly and transiently when cells are exposed to mitogenic

10 agents. This response appears correlated with an increase in sphingosine kinase activity in the cytosol and can be prevented by addition of the sphingosine kinase inhibitory molecules *N,N*-dimethylsphingosine and *DL-threo*-dihydrosphingosine. This indicates that sphingosine kinase is an important molecule responsible for regulating cellular sphingosine-1-phosphate levels. This places sphingosine kinase in a central and obligatory role in mediating the

15 effects attributed to sphingosine-1-phosphate in the cell.

Accordingly, there is a need to identify and clone novel sphingosine kinase molecules to facilitate the progression towards the more sensitive control of intracellular signal transduction via, for example, the elucidation of the mechanism controlling the expression

20 and enzymatic activity of sphingosine kinase thereby providing a platform for the development of interventional therapies to regulate the expression or activity of sphingosine kinase. In work leading up to the present invention the inventors have purified and cloned a novel sphingosine kinase molecule.

25 SUMMARY OF THE INVENTION

The subject specification contains nucleotide and amino acid sequence information prepared using the programme PatentIn Version 2.0, presented herein after the bibliography. Each nucleotide or amino acid sequence is identified in the sequence listing by the numeric

30 indicator <210> followed by the sequence identifier (e.g. <210>1, <210>2, etc). The length, type of sequence (DNA, protein (PRT), etc) and source organism for each nucleotide or

- 3 -

amino acid sequence are indicated by information provided in the numeric indicator fields <211>, <212> and <213>, respectively. Nucleotide and amino acid sequences referred to in the specification are defined by the information provided in numeric indicator field <400> followed by the sequence identifier (e.g. <400>1, <400>2, etc).

5

Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

10

One aspect of the present invention provides an isolated nucleic acid molecule or derivative or analogue thereof comprising a nucleotide sequence encoding or complementary to a sequence encoding a novel sphingosine kinase protein or a derivative or mimetic of said sphingosine kinase protein.

15

Another aspect of the present invention provides an isolated nucleic acid molecule or derivative or analogue thereof comprising a nucleotide sequence encoding or complementary to a sequence encoding a human sphingosine kinase protein or a derivative or mimetic of said sphingosine kinase protein.

20

Yet another aspect of the present invention provides a nucleic acid molecule or derivative or analogue thereof comprising a nucleotide sequence encoding, or a nucleotide sequence complementary to a nucleotide sequence encoding, an amino acid sequence substantially as set forth in <400>2 or a derivative or mimetic thereof or having at least about 45% or greater

25 similarity to at least 10 contiguous amino acids in <400>2.

Still another aspect of the present invention contemplates a nucleic acid molecule or derivative or analogue thereof comprising a nucleotide sequence substantially as set forth in <400>1 or a derivative thereof or capable of hybridising to <400>1 under low stringency

30 conditions.

- 4 -

Still yet another aspect of the present invention contemplates a nucleic acid molecule or derivative or analogue thereof comprising a nucleotide sequence substantially as set forth in <400>1 or a derivative thereof, or capable of hybridising to <400>1 under low stringency conditions and which encodes an amino acid sequence corresponding to an amino acid
5 sequence set forth in <400>2 or a sequence having at least about 45% similarity to at least 10 contiguous amino acids in <400>2.

A further aspect of the present invention contemplates a nucleic acid molecule comprising a sequence of nucleotides substantially as set forth in <400>1.

10

Another further aspect of the present invention contemplates a genomic nucleic acid molecule or derivative or analogue thereof capable of hybridising to <400>1 or a derivative thereof under low stringency conditions at 42°C.

15 Still another further aspect of the present invention provides a cDNA sequence comprising a sequence of nucleotides as set forth in <400>1 or a derivative or analogue thereof including a nucleotide sequence having similarity to <400>1.

Yet another further aspect of the present invention provides an amino acid sequence set forth
20 in <400>2 or a derivative, analogue or chemical equivalent or mimetic thereof as defined above or a derivative or mimetic having an amino acid sequence of at least about 45% similarity to at least 10 contiguous amino acids in the amino acid sequence as set forth in <400>2 or a derivative or mimetic thereof.

25 Stil yet another further aspect of the present invention is directed to an isolated protein selected from the list consisting of:

- (i) A novel sphingosine kinase protein or a derivative, analogue, chemical equivalent or mimetic thereof.

30

- 5 -

- (ii) A human sphingosine kinase protein or a derivative, analogue, chemical equivalent or mimetic thereof.
- (iii) A protein having an amino acid sequence substantially as set forth in <400>2 or a derivative or mimetic thereof or a sequence having at least about 45% similarity to at least 10 contiguous amino acids in <400>2 or a derivative, analogue, chemical equivalent or mimetic of said protein.
- (iv) A protein encoded by a nucleotide sequence substantially as set forth in <400>1 or a derivative or analogue thereof or a sequence encoding an amino acid sequence having at least about 45% similarity to at least 10 contiguous amino acids in <400>2 or a derivative, analogue, chemical equivalent or mimetic of said protein.
- (v) A protein encoded by a nucleic acid molecule capable of hybridising to the nucleotide sequence as set forth in <400>1 or a derivative or analogue thereof under low stringency conditions and which encodes an amino acid sequence substantially as set forth in <400>2 or a derivative or mimetic thereof or an amino acid sequence having at least about 45% similarity to at least 10 contiguous amino acids in <400>2.
- (vi) A protein as defined in paragraphs (i) or (ii) or (iii) or (iv) or (v) in a homodimeric form.
- (vii) A protein as defined in paragraphs (i) or (ii) or (iii) or (iv) or (v) in a heterodimeric form.

25

Another aspect of the present invention contemplates a method of modulating activity of sphingosine kinase in a mammal, said method comprising administering to said mammal a modulating effective amount of an agent for a time and under conditions sufficient to increase or decrease sphingosine kinase activity.

30

- 6 -

Still another aspect of the present invention contemplates a method of modulating cellular functional activity in a mammal said method comprising administering to said mammal an effective amount of an agent for a time and under conditions sufficient to modulate the expression of a nucleotide sequence encoding sphingosine kinase or sufficient to modulate
5 the activity of sphingosine kinase.

Yet another aspect of the present invention contemplates a method of modulating cellular functional activity in a mammal said method comprising administering to said mammal an effective amount of sphingosine kinase or *sphingosine kinase*.

10

Still yet another aspect of the present invention relates to a method of treating a mammal said method comprising administering to said mammal an effective amount of an agent for a time and under conditions sufficient to modulate the expression of *sphingosine kinase* or sufficient to modulate the activity of sphingosine kinase wherein said modulation results in
15 modulation of cellular functional activity.

A further aspect of the present invention relates to a method of treating a mammal said method comprising administering to said mammal an effective amount of sphingosine kinase or *sphingosine kinase* for a time and under conditions sufficient to modulate cellular
20 functional activity.

Yet another further aspect of the present invention relates to the use of an agent capable of modulating the expression of *sphingosine kinase* or modulating the activity of sphingosine kinase in the manufacture of a medicament for the modulation of cellular functional activity.
25

A further aspect of the present invention relates to the use of sphingosine kinase or *sphingosine kinase* in the manufacture of a medicament for the modulation of cellular functional activity.

- 7 -

Still yet another aspect of the present invention relates to agents for use in modulating *sphingosine kinase* expression or sphingosine kinase activity wherein said modulation results in modulation of cellular functional activity.

- 5 Another aspect of the present invention relates to sphingosine kinase or *sphingosine kinase* for use in modulating cellular functional activity.

In a related aspect of the present invention, the mammal undergoing treatment may be a human or an animal in need of therapeutic or prophylactic treatment.

10

In yet another further aspect the present invention contemplates a pharmaceutical composition comprising *sphingosine kinase*, sphingosine kinase or an agent capable of modulating *sphingosine kinase* expression or sphingosine kinase activity together with one or more pharmaceutically acceptable carriers and/or diluents. *Sphingosine kinase*,

- 15 sphingosine kinase or said agent are referred to as the active ingredients.

Yet another aspect of the present invention contemplates a method for detecting sphingosine kinase or *sphingosine kinase* mRNA in a biological sample from a subject said method comprising contacting said biological sample with an antibody specific for sphingosine
20 kinase or *sphingosine kinase* mRNA or its derivatives or homologs for a time and under conditions sufficient for an antibody-sphingosine kinase or antibody-sphingosine kinase mRNA complex to form, and then detecting said complex.

- 8 -

Single and three letter abbreviations used throughout the specification are defined in Table 1.

TABLE 1
Single and three letter amino acid abbreviations

5	Amino Acid	Three-letter Abbreviation	One-letter Symbol
	Alanine	Ala	A
10	Arginine	Arg	R
	Asparagine	Asn	N
	Aspartic acid	Asp	D
	Cysteine	Cys	C
	Glutamine	Gln	Q
15	Glutamic acid	Glu	E
	Glycine	Gly	G
	Histidine	His	H
	Isoleucine	Ile	I
	Leucine	Leu	L
20	Lysine	Lys	K
	Methionine	Met	M
	Phenylalanine	Phe	F
	Proline	Pro	P
	Serine	Ser	S
25	Threonine	The	T
	Tryptophan	Trp	W
	Tyrosine	Tyr	Y
	Valine	Val	V
30	Any residue	Xaa	X

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a schematic representation of the 'Sphingomyelin pathway'.

5 **Figure 2** is a graphical representation of anion exchange chromatography of human sphingosine kinase. *A*, Anion exchange chromatography with Q Sepharose fast flow of the $(\text{NH}_4)_2\text{SO}_4$ precipitated fraction of the human placenta extract showing two peaks of sphingosine kinase activity. Extracts were applied in buffer A and sphingosine kinase activity (•) was eluted with a NaCl gradient of 0 to 1M (----). Protein eluted was followed
10 by absorbance at 280 nm (—).

Figure 3 is a graphical representation of the purification of human placenta SKI by anion exchange chromatography. Purification on a Mono-Q column is enhanced by reapplication and elution from the same column in the presence of ATP. *A*, The fractions from the
15 calmodulin-Sepharose 4b column containing sphingosine kinase activity were pooled, desalted and applied to the Mono-Q column in buffer A. *B*, Active fractions from the Mono-Q column were desalted and reapplied to the Mono-Q column in buffer A with 1 mM ATP and 4mM MgCl_2 . In both cases sphingosine kinase activity (•) was eluted with a NaCl gradient of 0 to 1M (----), with protein elution followed by absorbance at 280 nm (—).

20

Figure 4 is an image of SDS-PAGE of purified human placenta sphingosine kinase. The fraction from the Superdex 75 column containing the highest sphingosine kinase activity was applied to SDS-PAGE with silver staining, yielding a single band of 45 kDa.

25 **Figure 5** is a graphical representation of preparative anion exchange chromatography. Only a single chromatographically identified sphingosine kinase isoform is present in HUVEC. Preparative anion exchange chromatography with HiTrap-Q columns of human placenta, HUVEC and $\text{TNF}\alpha$ treated HUVEC extracts showing, in HUVEC, the presence of a single sphingosine kinase peak that increases in activity following treatment of cells with $\text{TNF}\alpha$.
30 Cells were harvested, lysed and the soluble extracts applied to the HiTrap-Q column in buffer A. Total sphingosine kinase activity in human placenta, HUVEC and $\text{TNF}\alpha$ treated

- 10 -

HUVEC extracts were 51, 78 and 136 U/mg protein, respectively. Sphingosine kinase activity (\square) was eluted with a NaCl gradient of 0 to 1M (----).

Figure 6 is a schematic representation of the strategy used to clone sphingosine kinase (SPHK) from HUVEC.

Figure 7 is a schematic representation of the nucleotide (<400>1) and deduced amino acid (<400>2) sequences and putative domain structure of human sphingosine kinase. *A*, cDNA nucleic acid sequence and the deduced amino acid sequence of hSK. Amino acids are numbered from the first methionine residue. The stop codon is indicated by an asterisk. The sphingosine kinase coding region is in capital letters (nucleotides 33-1187), while lower case letters denote untranslated and vector sequence. *B*, Schematic representation of human sphingosine kinase showing locations of the putative PKC and CKII phosphorylation sites, a possible N-myristoylation site, calcium/calmodulin binding motifs and the region with similarity to the putative DGK catalytic domain.

Figure 8 is a graphical representation of the expression and TNF α stimulation of human sphingosine kinase activity in HEK293 cells. HEK293 cells transiently transfected with either empty pcDNA expression vector alone (*A*) or pcDNA containing human sphingosine kinase cDNA (*B*). Transfected cells were either untreated or treated with TNF α for 10 min, harvested and sphingosine kinase activity in cell lysates determined. Data are means of duplicates and are representative of three independent experiments.

Figure 9 is a schematic representation of the sequence comparison of human sphingosine kinase with other known and putative sphingosine kinases. Comparison of the deduced human sphingosine kinase amino acid sequence with the amino acid sequences of the murine (mSK1a and mSK1b; Kohama *et al.*, 1998) and *S. cerevisiae* (LCB4 and LCB5; Nagiec *et al.*, 1998) sphingosine kinases, and EST sequences of putative sphingosine kinases from *S. pombe* and *C. elegans* (GenbankTM accession numbers Z98762 and Z66494, respectively). Although the amino acid sequence similarity to human sphingosine kinase was high (36% identity), the *A. thaliana* putative sphingosine kinase sequence (GenbankTM accession

- 11 -

number AL022603) gave relatively poor alignment and, for clarity, is not shown. The consensus sequence represents amino acids that are conserved in at least six of the seven aligned sequences, while conservation of structurally similar amino acids are denoted with an asterisk. Multiple sequence alignment was performed with CLUSTALW, and percentage identities to the human sphingosine kinase were determined using the GAP algorithm (Needleman & Wunsch, 1970).

Figure 10 is an image of the expression of recombinant human sphingosine kinase in *E. coli* BL21. *E. coli* BL21 was transformed with the pGEX4-2T human sphingosine kinase expression construct and expression of the GST-SK fusion protein analysed after induction with 100 μ M IPTG. *A*, Sphingosine kinase activity in uninduced and IPTG induced *E. coli* BL21 cell extracts. *B*, Coomassie stained SDS-PAGE gel showing GST-SK fusion protein expression in *E. coli* cell lysates. *C*, Purity of the isolated recombinant human sphingosine kinase. The fraction from the Mono-Q column containing sphingosine kinase activity was applied to SDS-PAGE with silver staining yielding a single band of 45 kDa.

Figure 11 is an image of the purification of recombinant human sphingosine kinase. Calmodulin Sepharose 4B allows the separation of active and inactive enzyme. The GST-SK fusion protein was partially purified using glutathione-Sepharose 4B, cleaved by thrombin and applied to the calmodulin-Sepharose 4B column in Buffer B containing 4 mM CaCl_2 . Elution of the active sphingosine kinase bound to the column was performed with Buffer A containing 2 mM EGTA and 1 M NaCl. *A*, SDS-PAGE analysis of fractions eluted from the calmodulin-Sepharose 4B column. *B*, Sphingosine kinase activity in column fractions showing most of the recombinant human sphingosine kinase protein did not bind to the column and displayed no catalytic activity.

Figure 12 is a graphical representation of the physico-chemical properties of the native and recombinant sphingosine kinases. *A*, pH optima. The effect of pH on SK activity was determined by assaying the activity over the pH range of 4 to 11 in 50 mM buffers (sodium acetate, pH 4.0-5.0; Mes, pH 6.0-7.0; Hepes, pH 7.0-8.2; Tris/HCl, pH 8.2-10.0; Caps, pH 10.0-11.0). *B*, pH stability. Data shown is the SK activity remaining after preincubation of

the enzymes at various pH at 4°C for 5h. *C*, Temperature stability. Data shown is the SK activity remaining after preincubation of the enzymes at various temperatures (4 to 80°C) for 30 min at pH 7.4 (50mM Tris/HCl containing 10% glycerol, 0.5 M NaCl and 0.05% Triton X-100). *D*, Metal ion requirement. The various metal ions or EDTA were supplied in the

5 assay mixture at a final concentration of 10 mM. In all cases the maximum activities of the native (□ and filled bars) and recombinant (□ and open bars) sphingosine kinases were arbitrarily set at 100% and correspond to 2.65 kU and 7.43 kU, respectively. Data are means ± S.D.

- 10 **Figure 13** is a graphical representation of the substrate specificity and kinetics of the native and recombinant sphingosine kinases. *A*, Substrate specificity of the native (filled bars) and recombinant (open bars) sphingosine kinases with sphingosine analogues and other lipids supplied at 100 µM in 0.25% Triton X-100. The rates of phosphorylation of sphingosine by the native and recombinant Sks were arbitrarily set at 100% and correspond to 2.65 kU and
- 15 7.43 kU, respectively. Activity against other potential substrates were expressed relative to the activity against sphingosine. No phosphorylation was observed with DL-*threo*-dihydrosphingosine, *N,N*-dimethylsphingosine, *N,N,N*-trimethylsphingosine, *N*-acetylsphingosine (*C*₂-ceramide), diacylglycerol (1,2-dioctanoyl-*sn*-glycerol and 1,2-dioleoyl-*sn*-glycerol), and phosphatidylinositol. *B*, Substrate kinetics of the recombinant
- 20 human sphingosine kinase with sphingosine (□) and D-*erythro*-dihydrosphingosine (□) as substrates. *C*, Kinetics of inhibition of the recombinant human sphingosine kinase with *N,N,N*-trimethylsphingosine at 5 µM (□) and 25 µM (□), and in the absence of *N,N,N*-trimethylsphingosine (□). Inset: Lineweaver-Burk plot. Data are means ± S.D.
- 25 **Figure 14** is a graphical representation of the acidic phospholipids which stimulate the activity of the native and recombinant sphingosine kinases. The effect of various phospholipids on the activity of the native and recombinant sphingosine kinases were determined by assaying the activity under standard conditions in the presence of these phospholipids at 10 mol% of Triton X-100. The activities of the native (filled bars) and
- 30 recombinant (open bars) sphingosine kinases in the absence of phospholipids were arbitrarily set at 100% and correspond to 2.65 kU and 7.43 kU, respectively. PC, phosphatidylcholine;

- 13 -

PS, phosphatidylserine; PE, phosphatidylethanolamine; PI phosphatidylinositol; PA, phosphatidic acid. Data are means \pm S.D.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is predicated, in part, on the purification and cloning of a novel sphingosine kinase molecule. The identification of this novel molecule permits the
5 identification and rational design of a range of products for use in therapy, diagnosis and antibody generation, for example for use in signal transduction. These therapeutic molecules may also act as either antagonists or agonists of sphingosine kinase function and will be useful, *inter alia*, in the modulation of cellular activation in the treatment of disease conditions characterised by unwanted cellular activity.

10

Accordingly, one aspect of the present invention provides an isolated nucleic acid molecule or derivative or analogue thereof comprising a nucleotide sequence encoding or complementary to a sequence encoding a novel sphingosine kinase protein or a derivative or mimetic of said sphingosine kinase protein.

15

Reference to "sphingosine kinase" should be understood as a reference to the molecule which is, *inter alia*, involved in the generation of sphingosine-1-phosphate during the activation of the sphingosine kinase signalling pathway. Reference to "*sphingosine kinase*" in italicised text should be understood as a reference to the sphingosine kinase nucleic acid
20 molecule. Reference to "sphingosine kinase" in non-italicised text should be understood as a reference to the sphingosine kinase protein molecule.

More particularly, the present invention provides an isolated nucleic acid molecule or derivative or analogue thereof comprising a nucleotide sequence encoding of complementary
25 to a sequence encoding a human sphingosine kinase protein or a derivative or mimetic of said sphingosine kinase protein.

In a preferred embodiment, the present invention provides a nucleic acid molecule or derivative or analogue thereof comprising a nucleotide sequence encoding, or a nucleotide
30 sequence complementary to a nucleotide sequence encoding, an amino acid sequence

- 15 -

substantially as set forth in <400>2 or a derivative or mimetic thereof or having at least about 45% or greater similarity to at least 10 contiguous amino acids in <400>2.

The term "similarity" as used herein includes exact identity between compared sequences at the nucleotide or amino acid level. Where there is non-identity at the nucleotide level, "similarity" includes differences between sequences which result in different amino acids that are nevertheless related to each other at the structural, functional, biochemical and/or conformational levels. Where there is non-identity at the amino acid level, "similarity" includes amino acids that are nevertheless related to each other at the structural, functional, biochemical and/or conformational levels. The percentage similarity may be greater than 50% such as at least 70% or at least 80% or at least 90% or at least 95% or higher.

Another aspect of the present invention contemplates a nucleic acid molecule or derivative or analogue thereof comprising a nucleotide sequence substantially as set forth in <400>1 or a derivative thereof, or capable of hybridising to <400>1 under low stringency conditions.

Reference herein to a low stringency includes and encompasses from at least about 0% v/v to at least about 15% v/v formamide and from at least about 1M to at least about 2M salt for hybridisation, and at least about 1M to at least about 2M salt for washing conditions.

Alternative stringency conditions may be applied where necessary, such as medium stringency, which includes and encompasses from at least about 16% v/v to at least about 30% v/v formamide and from at least about 0.5M to at least about 0.9M salt for hybridisation, and at least about 0.5M to at least about 0.9M salt for washing conditions, or high stringency, which includes and encompasses from at least about 31% v/v to at least about 50% v/v formamide and from at least about 0.01M to at least about 0.15M salt for hybridisation, and at least about 0.01M to at least about 0.15M salt for washing conditions. Stringency may be measured using a range of temperature such as from about 40°C to about 65°C. Particularly useful stringency conditions are at 42°C. In general, washing is carried out at $T_m = 69.3 + 0.41 (G + C) \% [19] = -12^\circ\text{C}$. However, the T_m of a duplex DNA decreases by 1°C with every increase of 1% in the number of mismatched based pairs (Bonner *et al* (1973) *J.Mol.Biol*, 81:123).

- 16 -

Preferably, the present invention contemplates a nucleic acid molecule or derivative or analogue thereof comprising a nucleotide sequence substantially as set forth in <400>1 or a derivative thereof or capable of hybridising to <400>1 under low stringency conditions and which encodes an amino acid sequence corresponding to an amino acid sequence set forth in
5 <400>2 or a sequence having at least about 45% similarity to at least 10 contiguous amino acids in <400>2.

More particularly, the present invention contemplates a nucleic acid molecule comprising a sequence of nucleotides substantially as set forth in <400>1.

10

The nucleic acid molecule according to this aspect of the present invention corresponds herein to human *sphingosine kinase*. Without limiting the present invention to any one theory or mode of action, the protein encoded by *sphingosine kinase* is a key element in the functioning of the sphingosine kinase signalling pathway. Sphingosine kinase acts to
15 facilitate the generation of the second messenger, sphingosine-1-phosphate, and may be activated by:

- (a) post-translational modifications such as phosphorylation or proteolytic cleavage;
- 20 (b) protein-protein interactions such as dimerisation, and G protein-coupled receptor mediated interactions;
- (c) translocational events where the enzyme is targeted to an environment that increases catalytic activity or allows access to its substrate.

25

The expression product of the human *sphingosine kinase* nucleic acid molecule is human sphingosine kinase. Sphingosine kinase is defined by the amino acid sequence set forth in <400>2. The cDNA sequence for sphingosine kinase is defined by the nucleotide sequence set forth in <400>1. The nucleic acid molecule encoding sphingosine kinase is preferably a
30 sequence of deoxyribonucleic acids such as a cDNA sequence or a genomic sequence. A

- 17 -

genomic sequence may also comprise exons and introns. A genomic sequence may also include a promoter region or other regulatory regions.

Another aspect of the present invention contemplates a genomic nucleic acid molecule or
5 derivative thereof capable of hybridising to <400>1 or a derivative thereof under low stringency conditions at 42°C.

Reference herein to sphingosine kinase and *sphingosine kinase* should be understood as a reference to all forms of human sphingosine kinase and *sphingosine kinase*, respectfully,
10 including, for example, any peptide and cDNA isoforms which arise from alternative splicing of *sphingosine kinase* mRNA, mutants or polymorphic variants of *sphingosine kinase* or sphingosine kinase, the post-translation modified form of sphingosine kinase or the non-post-translation modified form of sphingosine kinase. To the extent that it is not specified, reference herein to sphingosine kinase and *sphingosine kinase* includes reference
15 to derivatives, analogues, chemical equivalents and mimetics thereof.

The protein and/or gene is preferably from the human. However, the protein and/or gene may also be isolated from other animal or non-animal species.

20 Derivatives include fragments, parts, portions, mutants, variants and mimetics from natural, synthetic or recombinant sources including fusion proteins. Parts or fragments include, for example, active regions of sphingosine kinase. Derivatives may be derived from insertion, deletion or substitution of amino acids. Amino acid insertional derivatives include amino and/or carboxylic terminal fusions as well as intrasequence insertions of single or multiple
25 amino acids. Insertional amino acid sequence variants are those in which one or more amino acid residues are introduced into a predetermined site in the protein although random insertion is also possible with suitable screening of the resulting product. Deletional variants are characterized by the removal of one or more amino acids from the sequence.

Substitutional amino acid variants are those in which at least one residue in the sequence has
30 been removed and a different residue inserted in its place. An example of substitutional amino acid variants are conservative amino acid substitutions. Conservative amino acid

- 18 -

substitutions typically include substitutions within the following groups: glycine and alanine; valine, isoleucine and leucine; aspartic acid and glutamic acid; asparagine and glutamine; serine and threonine; lysine and arginine; and phenylalanine and tyrosine. Additions to amino acid sequences including fusions with other peptides, polypeptides or proteins.

5

Chemical and functional equivalents of *sphingosine kinase* or sphingosine kinase should be understood as molecules exhibiting any one or more of the functional activities of *sphingosine kinase* or sphingosine kinase and may be derived from any source such as being chemically synthesized or identified via screening processes such as natural product

10 screening.

The derivatives of sphingosine kinase include fragments having particular epitopes or parts of the entire sphingosine kinase protein fused to peptides, polypeptides or other proteinaceous or non-proteinaceous molecules.

15

Analogues of sphingosine kinase contemplated herein include, but are not limited to, modification to side chains, incorporating of unnatural amino acids and/or their derivatives during peptide, polypeptide or protein synthesis and the use of crosslinkers and other methods which impose conformational constraints on the proteinaceous molecules or their

20 analogues.

Derivatives of nucleic acid sequences may similarly be derived from single or multiple nucleotide substitutions, deletions and/or additions including fusion with other nucleic acid molecules. The derivatives of the nucleic acid molecules of the present invention include

25 oligonucleotides, PCR primers, antisense molecules, molecules suitable for use in cosuppression and fusion of nucleic acid molecules. Derivatives of nucleic acid sequences also include degenerate variants.

Examples of side chain modifications contemplated by the present invention include

30 modifications of amino groups such as by reductive alkylation by reaction with an aldehyde followed by reduction with NaBH_4 ; amidination with methylacetimidate; acylation with

- 19 -

acetic anhydride; carbamoylation of amino groups with cyanate; trinitrobenzylation of amino groups with 2, 4, 6-trinitrobenzene sulphonic acid (TNBS); acylation of amino groups with succinic anhydride and tetrahydrophthalic anhydride; and pyridoxylation of lysine with pyridoxal-5-phosphate followed by reduction with NaBH_4 .

5

The guanidine group of arginine residues may be modified by the formation of heterocyclic condensation products with reagents such as 2,3-butanedione, phenylglyoxal and glyoxal.

The carboxyl group may be modified by carbodiimide activation *via* O-acylisourea.

10 formation followed by subsequent derivitisation, for example, to a corresponding amide.

Sulphydryl groups may be modified by methods such as carboxymethylation with iodoacetic acid or iodoacetamide; performic acid oxidation to cysteic acid; formation of a mixed disulphides with other thiol compounds; reaction with maleimide, maleic anhydride or other substituted maleimide; formation of mercurial derivatives using 4-chloromercuribenzoate, 15 4-chloromercuriphenylsulphonic acid, phenylmercury chloride, 2-chloromercuri-4-nitrophenol and other mercurials; carbamoylation with cyanate at alkaline pH.

20 Tryptophan residues may be modified by, for example, oxidation with N-bromosuccinimide or alkylation of the indole ring with 2-hydroxy-5-nitrobenzyl bromide or sulphenyl halides.

Tyrosine residues on the other hand, may be altered by nitration with tetranitromethane to form a 3-nitrotyrosine derivative.

25 Modification of the imidazole ring of a histidine residue may be accomplished by alkylation with iodoacetic acid derivatives or N-carboethoxylation with diethylpyrocarbonate.

Examples of incorporating unnatural amino acids and derivatives during protein synthesis include, but are not limited to, use of norleucine, 4-amino butyric acid, 4-amino-3-hydroxy-5-phenylpentanoic acid, 6-aminohexanoic acid, t-butylglycine, norvaline, phenylglycine, 30 ornithine, sarcosine, 4-amino-3-hydroxy-6-methylheptanoic acid, 2-thienyl alanine and/or D-

- 20 -

isomers of amino acids. A list of unnatural amino acid contemplated herein is shown in Table 2.

- 21 -

TABLE 2

Non-conventional amino acid		Code	Non-conventional amino acid		Code
5					
	α -aminobutyric acid	Abu	L-N-methylalanine		Nmala
	α -amino- α -methylbutyrate	Mgab	L-N-methylarginine		Nmarg
	aminocyclopropane-carboxylate	Cpro	L-N-methylasparagine		Nmasn
			L-N-methylaspartic acid		Nmasp
10	aminoisobutyric acid	Aib	L-N-methylcysteine		Nmcys
	aminonorbonyl-carboxylate	Norb	L-N-methylglutamine		Nmgln
			L-N-methylglutamic acid		Nmglu
	cyclohexylalanine		Chexa L-N-methylhistidine		Nmhis
	cyclopentylalanine	Cpen	L-N-methylisoleucine		Nmile
15	D-alanine	Dal	L-N-methylleucine		Nmleu
	D-arginine	Darg	L-N-methyllysine		Nmlys
	D-aspartic acid	Dasp	L-N-methylmethionine		Nmmet
	D-cysteine	Dcys	L-N-methylnorleucine		Nmnle
	D-glutamine	Dgln	L-N-methylnorvaline		Nmnva
20	D-glutamic acid	Dglu	L-N-methylornithine		Nmorn
	D-histidine	Dhis	L-N-methylphenylalanine		Nmphe
	D-isoleucine	Dile	L-N-methylproline		Nmpro
	D-leucine	Dleu	L-N-methylserine		Nmser
	D-lysine	Dlys	L-N-methylthreonine		Nmthr
25	D-methionine	Dmet	L-N-methyltryptophan		Nmtrp
	D-ornithine	Dorn	L-N-methyltyrosine		Nmtyr
	D-phenylalanine	Dphe	L-N-methylvaline		Nmval
	D-proline	Dpro	L-N-methylethylglycine		Nmetg
	D-serine	Dser	L-N-methyl-t-butylglycine		Nmtbug
30	D-threonine	Dthr	L-norleucine		Nle
	D-tryptophan	Dtrp	L-norvaline		Nva
	D-tyrosine	Dtyr	α -methyl-aminoisobutyrate		Maib
	D-valine	Dval	α -methyl- γ -aminobutyrate		Mgab

- 22 -

	D- α -methylalanine	Dmala	α -methylcyclohexylalanine	Mchexa
	D- α -methylarginine	Dmarg	α -methylcyclopentylalanine	Mcpen
	D- α -methylassparagine	Dmasn	α -methyl- α -naphthylalanine	Manap
	D- α -methylaspartate	Dmasp	α -methylpenicillamine	Mpen
5	D- α -methylcysteine	Dmcys	N-(4-aminobutyl)glycine	Nglu
	D- α -methylglutamine	Dmgln	N-(2-aminoethyl)glycine	Naeg
	D- α -methylhistidine	Dmhis	N-(3-aminopropyl)glycine	Norn
	D- α -methylisoleucine	Dmile	N-amino- α -methylbutyrate	Nmaabu
	D- α -methyllleucine	Dmleu	α -naphthylalanine	Anap
10	D- α -methyllysine	Dmlys	N-benzylglycine	Nphe
	D- α -methylmethionine	Dmmet	N-(2-carbamylethyl)glycine	Ngln
	D- α -methylornithine	Dmorn	N-(carbamylmethyl)glycine	Nasn
	D- α -methylphenylalanine	Dmphe	N-(2-carboxyethyl)glycine	Nglu
	D- α -methylproline	Dmpro	N-(carboxymethyl)glycine	Nasp
15	D- α -methylserine	Dmser	N-cyclobutylglycine	Ncbut
	D- α -methylthreonine	Dmthr	N-cycloheptylglycine	Nchep
	D- α -methyltryptophan	Dmtrp	N-cyclohexylglycine	Nchex
	D- α -methyltyrosine	Dmtty	N-cyclodecylglycine	Ncdec
	D- α -methylvaline	Dmval	N-cylcododecylglycine	Ncdod
20	D-N-methylalanine	Dnmala	N-cyclooctylglycine	Ncoct
	D-N-methylarginine	Dnmarg	N-cyclopropylglycine	Ncpro
	D-N-methylassparagine	Dnmasn	N-cycloundecylglycine	Ncund
	D-N-methylaspartate	Dnmasp	N-(2,2-diphenylethyl)glycine	Nbhm
	D-N-methylcysteine	Dnmcys	N-(3,3-diphenylpropyl)glycine	Nbhe
25	D-N-methylglutamine	Dnmgln	N-(3-guanidinopropyl)glycine	Narg
	D-N-methylglutamate	Dnmglu	N-(1-hydroxyethyl)glycine	Nthr
	D-N-methylhistidine	Dnmhis	N-(hydroxyethyl)glycine	Nser
	D-N-methylisoleucine	Dnmile	N-(imidazolylethyl)glycine	Nhis
	D-N-methyllleucine	Dnmleu	N-(3-indolylethyl)glycine	Nhtrp
30	D-N-methyllysine	Dnmlys	N-methyl- γ -aminobutyrate	Nmgabu
	N-methylcyclohexylalanine	Nmchexa	D-N-methylmethionine	Dnmmet
	D-N-methylornithine	Dnmorn	N-methylcyclopentylalanine	Nmcpen
	N-methylglycine	Nala	D-N-methylphenylalanine	Dnmphe

- 23 -

	N-methylaminoisobutyrate	Nmaib	D-N-methylproline	Dnmpro
	N-(1-methylpropyl)glycine	Nile	D-N-methylserine	Dnmser
	N-(2-methylpropyl)glycine	Nleu	D-N-methylthreonine	Dnmthr
	D-N-methyltryptophan	Dnmtrp	N-(1-methylethyl)glycine	Nval
5	D-N-methyltyrosine	Dnmtyr	N-methyl- α -naphthylalanine	Nmanap
	D-N-methylvaline	Dnmval	N-methylpenicillamine	Nmpen
	γ -aminobutyric acid	Gabu	N-(<i>p</i> -hydroxyphenyl)glycine	Nhtyr
	L- <i>t</i> -butylglycine	Tbug	N-(thiomethyl)glycine	Ncys
	L-ethylglycine	Etg	penicillamine	Pen
10	L-homophenylalanine	Hphe	L- α -methylalanine	Mala
	L- α -methylarginine	Marg	L- α -methylasparagine	Masn
	L- α -methylaspartate	Masp	L- α -methyl- <i>t</i> -butylglycine	Mtbug
	L- α -methylcysteine	Mcys	L-methylethylglycine	Metg
	L- α -methylglutamine	Mgln	L- α -methylglutamate	Mglu
15	L- α -methylhistidine	Mhis	L- α -methylhomophenylalanine	Mhphe
	L- α -methylisoleucine	Mile	N-(2-methylthioethyl)glycine	Nmet
	L- α -methyllleucine	Mleu	L- α -methyllysine	Mlys
	L- α -methylmethionine	Mmet	L- α -methylnorleucine	Mnle
	L- α -methylnorvaline	Mnva	L- α -methylornithine	Morn
20	L- α -methylphenylalanine	Mphe	L- α -methylproline	Mpro
	L- α -methylserine	Mser	L- α -methylthreonine	Mthr
	L- α -methyltryptophan	Mtrp	L- α -methyltyrosine	Mtyr
	L- α -methylvaline	Mval	L-N-methylhomophenylalanine	Nmhphe
	N-(N-(2,2-diphenylethyl)	Nnbhm	N-(N-(3,3-diphenylpropyl)	Nnbhe
25	carbamylmethyl)glycine		carbamylmethyl)glycine	
	1-carboxy-1-(2,2-diphenyl-Nmbc			
	ethylamino)cyclopropane			

Crosslinkers can be used, for example, to stabilise 3D conformations, using homo-

30 bifunctional crosslinkers such as the bifunctional imido esters having (CH₂)_n spacer groups with n=1 to n=6, glutaraldehyde, N-hydroxysuccinimide esters and hetero-bifunctional

- 24 -

reagents which usually contain an amino-reactive moiety such as N-hydroxysuccinimide and another group specific-reactive moiety.

The nucleic acid molecule of the present invention is preferably in isolated form or ligated
5 to a vector, such as an expression vector. By "isolated" is meant a nucleic acid molecule having undergone at least one purification step and this is conveniently defined, for example, by a composition comprising at least about 10% subject nucleic acid molecule, preferably at least about 20%, more preferably at least about 30%, still more preferably at least about 40-50%, even still more preferably at least about 60-70%, yet even still more
10 preferably 80-90% or greater of subject nucleic acid molecule relative to other components as determined by molecular weight, encoding activity, nucleotide sequence, base composition or other convenient means. The nucleic acid molecule of the present invention may also be considered, in a preferred embodiment, to be biologically pure.

15 The term "protein" should be understood to encompass peptides, polypeptides and proteins. The protein may be glycosylated or unglycosylated and/or may contain a range of other molecules fused, linked, bound or otherwise associated to the protein such as amino acids, lipids, carbohydrates or other peptides, polypeptides or proteins. Reference hereinafter to a "protein" includes a protein comprising a sequence of amino acids as well as a protein
20 associated with other molecules such as amino acids, lipids, carbohydrates or other peptides, polypeptides or proteins.

In a particularly preferred embodiment, the nucleotide sequence corresponding to *sphingosine kinase* is a cDNA sequence comprising a sequence of nucleotides as set forth
25 in <400>1 or a derivative or analogue thereof including a nucleotide sequence having similarity to <400>1.

A derivative of a nucleic acid molecule of the present invention also includes a nucleic acid molecule capable of hybridising to a nucleotide sequence as set forth in <400>1 under low
30 stringency conditions. Preferably, low stringency is at 42°C.

- 25 -

The nucleic acid molecule may be ligated to an expression vector capable of expression in a prokaryotic cell (e.g. *E.coli*) or a eukaryotic cell (e.g. yeast cells, fungal cells, insect cells, mammalian cells or plant cells). The nucleic acid molecule may be ligated or fused or otherwise associated with a nucleic acid molecule encoding another entity such as, for example, a signal peptide. It may also comprise additional nucleotide sequence information fused, linked or otherwise associated with it either at the 3' or 5' terminal portions or at both the 3' and 5' terminal portions. The nucleic acid molecule may also be part of a vector, such as an expression vector. The latter embodiment facilitates production of recombinant forms of sphingosine kinase which forms are encompassed by the present invention.

10

The present invention extends to the expression product of the nucleic acid molecules as hereinbefore defined.

The expression product is sphingosine kinase having an amino acid sequence set forth in <400>2 or is a derivative, analogue or chemical equivalent or mimetic thereof as defined above or is a derivative or mimetic having an amino acid sequence of at least about 45% similarity to at least 10 contiguous amino acids in the amino acid sequence as set forth in <400>2 or a derivative or mimetic thereof.

20 Another aspect of the present invention is directed to an isolated protein selected from the list consisting of:

(i) A novel sphingosine kinase protein or a derivative, analogue, chemical equivalent or mimetic thereof.

25

(ii) A human sphingosine kinase protein or a derivative, analogue, chemical equivalent or mimetic thereof.

(iii) A protein having an amino acid sequence substantially as set forth in <400>2 or a derivative or mimetic thereof or a sequence having at least about 45% similarity to

30

- 26 -

at least 10 contiguous amino acids in <400>2 or a derivative, analogue, chemical equivalent or mimetic of said protein.

- (iv) A protein encoded by a nucleotide sequence substantially as set forth in <400>1 or a derivative or analogue thereof or a sequence encoding an amino acid sequence having at least about 45% similarity to at least 10 contiguous amino acids in <400>2 or a derivative, analogue, chemical equivalent or mimetic of said protein.
- (v) A protein encoded by a nucleic acid molecule capable of hybridising to the nucleotide sequence as set forth in <400>1 or a derivative or analogue thereof under low stringency conditions and which encodes an amino acid sequence substantially as set forth in <400>2 or a derivative or mimetic thereof or an amino acid sequence having at least about 45% similarity to at least 10 contiguous amino acids in <400>2.
- (vi) A protein as defined in paragraphs (i) or (ii) or (iii) or (iv) or (v) in a homodimeric form.
- (vii) A protein as defined in paragraphs (i) or (ii) or (iii) or (iv) or (v) in a heterodimeric form.

The protein of the present invention is preferably in isolated form. By "isolated" is meant a protein having undergone at least one purification step and this is conveniently defined, for example, by a composition comprising at least about 10% subject protein, preferably at least about 20%, more preferably at least about 30%, still more preferably at least about 40-50%, even still more preferably at least about 60-70%, yet even still more preferably 80-90% or greater of subject protein relative to other components as determined by molecular weight, amino acid sequence or other convenient means. The protein of the present invention may also be considered, in a preferred embodiment, to be biologically pure.

- 27 -

The sphingosine kinase of the present invention may be in multimeric form meaning that two or more molecules are associated together. Where the same sphingosine kinase molecules are associated together, the complex is a homomultimer. An example of a homomultimer is a homodimer. Where at least one sphingosine kinase is associated with at least one non- sphingosine kinase molecule, then the complex is a heteromultimer such as a heterodimer.

The ability to produce recombinant sphingosine kinase permits the large scale production of sphingosine kinase for commercial use. The sphingosine kinase may need to be produced as part of a large peptide, polypeptide or protein which may be used as is or may first need to be processed in order to remove the extraneous proteinaceous sequences. Such processing includes digestion with proteases, peptidases and amidases or a range of chemical, electrochemical, sonic or mechanical disruption techniques.

Notwithstanding that the present invention encompasses recombinant proteins, chemical synthetic techniques are also preferred in synthesis of sphingosine kinase.

Sphingosine kinase according to the present invention is conveniently synthesised based on molecules isolated from the human. Isolation of the human molecules may be accomplished by any suitable means such as by chromatographic separation, for example using CM-cellulose ion exchange chromatography followed by Sephadex (e.g. G-50 column) filtration. Many other techniques are available including HPLC, PAGE amongst others.

Sphingosine kinase may be synthesised by solid phase synthesis using F-moc chemistry as described by Carpino *et al.* (1991). Sphingosine kinase and fragments thereof may also be synthesised by alternative chemistries including, but not limited to, t-Boc chemistry as described in Stewart *et al.* (1985) or by classical methods of liquid phase peptide synthesis.

Without limiting the theory or mode of action of the present invention, sphingosine kinase is a key regulatory enzyme in the activity of the sphingosine kinase signalling pathway. By

- 28 -

"sphingosine kinase signalling pathway" is meant a signalling pathway which utilises one or both of sphingosine kinase and/or sphingosine-1-phosphate. It is thought that a sphingosine kinase signalling pathway cascade which results in adhesion molecule expression may take the form of:

5

(i) the generation of ceramide from sphingomyelin via *S.Mase* activity, said ceramide being converted to sphingosine;

10

(ii) sphingosine-1-phosphate (referred to hereinafter as "Sph-1-P") generation by stimulation of sphingosine kinase; and

(iii) the activation of MEK/ERK and nuclear translocation of NF- κ B downstream from Sph-1-P generation.

15 The sphingosine kinase signalling pathway is known to regulate cellular activities such as those which lead to inflammation, apoptosis and cell proliferation. For example, upregulation of the production of inflammatory mediators such as cytokines, chemokines, eNOS and upregulation of adhesion molecule expression. Said upregulation may be induced by a number of stimuli including, for example, inflammatory cytokines such as
20 tumour necrosis factor- α (TNF- α) and interleukin-1 (IL-1), endotoxin, oxidised or modified lipids, radiation or tissue injury.

The cloning and sequencing of this gene and its expression product now provides additional molecules for use in the prophylactic and therapeutic treatment of diseases
25 characterised by unwanted cellular activity, which activity is either directly or indirectly modulated via the activity of the sphingosine kinase signalling pathway. Examples of diseases involving unwanted sphingosine kinase regulated cellular activity include rheumatoid arthritis, asthma, atherosclerosis, meningitis, multiple sclerosis and septic shock. Accordingly, the present invention contemplates therapeutic and prophylactic uses
30 of sphingosine kinase amino acid and nucleic acid molecules, in addition to sphingosine

- 29 -

kinase agonistic and antagonistic agents. for the regulation of cellular functional activity, such as for example, regulation of inflammation.

The present invention contemplates, therefore, a method for modulating expression of
5 *sphingosine kinase* in a subject, said method comprising contacting the *sphingosine kinase* gene with an effective amount of an agent for a time and under conditions sufficient to up-regulate or down-regulate or otherwise modulate expression of *sphingosine kinase*. For example, *sphingosine kinase* antisense sequences such as oligonucleotides may be introduced into a cell to down-regulate one or more specific functional activities of that
10 cell. Conversely, a nucleic acid molecule encoding sphingosine kinase or a derivative thereof may be introduced to up-regulate one or more specific functional activities of any cell not expressing the endogenous *sphingosine kinase* gene.

Another aspect of the present invention contemplates a method of modulating activity of
15 sphingosine kinase in a mammal, said method comprising administering to said mammal a modulating effective amount of an agent for a time and under conditions sufficient to increase or decrease sphingosine kinase activity.

Modulation of said activity by the administration of an agent to a mammal can be achieved
20 by one of several techniques, including but in no way limited to introducing into said mammal a proteinaceous or non-proteinaceous molecule which:

- (i) modulates expression of *sphingosine kinase*;
- 25 (ii) functions as an antagonist of sphingosine kinase;
- (iii) functions as an agonist of sphingosine kinase.

Said proteinaceous molecule may be derived from natural or recombinant sources including
30 fusion proteins or following, for example, natural product screening. Said non-proteinaceous molecule may be, for example, a nucleic acid molecule or may be derived

- 30 -

from natural sources, such as for example natural product screening or may be chemically synthesised. The present invention contemplates chemical analogs of sphingosine kinase or small molecules capable of acting as agonists or antagonists of sphingosine kinase.

Chemical agonists may not necessarily be derived from sphingosine kinase but may share
5 certain conformational similarities. Alternatively, chemical agonists may be specifically designed to mimic certain physiochemical properties of sphingosine kinase. Antagonists may be any compound capable of blocking, inhibiting or otherwise preventing sphingosine kinase from carrying out its normal biological functions. Antagonists include monoclonal
10 antibodies specific for sphingosine kinase, or parts of sphingosine kinase, and antisense nucleic acids which prevent transcription or translation of *sphingosine kinase* genes or mRNA in mammalian cells. Modulation of *sphingosine kinase* expression may also be achieved utilising antigens, RNA, ribosomes, DNazymes, RNA aptamers or antibodies.

Said proteinaceous or non-proteinaceous molecule may act either directly or indirectly to
15 modulate the expression of *sphingosine kinase* or the activity of sphingosine kinase. Said molecule acts directly if it associates with *sphingosine kinase* or sphingosine kinase to modulate the expression or activity of *sphingosine kinase* or sphingosine kinase. Said molecule acts indirectly if it associates with a molecule other than *sphingosine kinase* or sphingosine kinase which other molecule either directly or indirectly modulates the
20 expression or activity of *sphingosine kinase* or sphingosine kinase. Accordingly, the method of the present invention encompasses the regulation of *sphingosine kinase* or sphingosine kinase expression or activity via the induction of a cascade of regulatory steps which lead to the regulation of *sphingosine kinase* or sphingosine kinase expression or activity.

25

Another aspect of the present invention contemplates a method of modulating cellular functional activity in a mammal said method comprising administering to said mammal an effective amount of an agent for a time and under conditions sufficient to modulate the expression of a nucleotide sequence encoding sphingosine kinase or sufficient to modulate
30 the activity of sphingosine kinase.

- 31 -

Yet another aspect of the present invention contemplates a method of modulating cellular functional activity in a mammal said method comprising administering to said mammal an effective amount of sphingosine kinase or *sphingosine kinase*.

- 5 The sphingosine kinase, *sphingosine kinase* or agent used may also be linked to a targeting means such as a monoclonal antibody, which provides specific delivery of the sphingosine kinase, *sphingosine kinase* or agent to the target cells.

In a preferred embodiment of the present invention, the sphingosine kinase, *sphingosine*
10 *kinase* or agent used in the method is linked to an antibody specific for said target cells to enable specific delivery to these cells.

Reference to "modulating cellular functional activity" is a reference to up-regulating, down-regulating or otherwise altering any one or more of the activities which a cell is capable of
15 performing such as, but not limited to, one or more of chemokine production, cytokine production, nitric oxide synthetase, adhesion molecule expression and production of other inflammatory modulators.

Administration of the sphingosine kinase, *sphingosine kinase* or agent, in the form of a
20 pharmaceutical composition, may be performed by any convenient means. Sphingosine kinase, *sphingosine kinase* or agent of the pharmaceutical composition are contemplated to exhibit therapeutic activity when administered in an amount which depends on the particular case. The variation depends, for example, on the human or animal and the sphingosine kinase, *sphingosine kinase* or agent chosen. A broad range of doses may be
25 applicable. Considering a patient, for example, from about 0.1 mg to about 1 mg of sphingosine kinase or agent may be administered per kilogram of body weight per day. Dosage regimes may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily, weekly, monthly or other suitable time intervals or the dose may be proportionally reduced as indicated by the
30 exigencies of the situation. The sphingosine kinase or agent may be administered in a convenient manner such as by the oral, intravenous (where water soluble), intranasal,

- 32 -

intraperitoneal, intramuscular, subcutaneous, intradermal or suppository routes or implanting (e.g. using slow release molecules). With particular reference to use of sphingosine kinase or agent, these peptides may be administered in the form of pharmaceutically acceptable nontoxic salts, such as acid addition salts or metal complexes, e.g. with zinc, iron or the like (which are considered as salts for purposes of this application). Illustrative of such acid addition salts are hydrochloride, hydrobromide, sulphate, phosphate, maleate, acetate, citrate, benzoate, succinate, malate, ascorbate, tartrate and the like. If the active ingredient is to be administered in tablet form, the tablet may contain a binder such as tragacanth, corn starch or gelatin; a disintegrating agent, such as alginic acid; and a lubricant, such as magnesium stearate.

A further aspect of the present invention relates to the use of the invention in relation to mammalian disease conditions. For example, the present invention is particularly useful, but in no way limited to, use in inflammatory diseases.

15

Accordingly, another aspect of the present invention relates to a method of treating a mammal said method comprising administering to said mammal an effective amount of an agent for a time and under conditions sufficient to modulate the expression of *sphingosine kinase* or sufficient to modulate the activity of sphingosine kinase wherein said modulation results in modulation of cellular functional activity.

20

In another aspect the present invention relates to a method of treating a mammal said method comprising administering to said mammal an effective amount of sphingosine kinase or *sphingosine kinase* for a time and under conditions sufficient to modulate cellular functional activity.

25

Yet another aspect of the present invention relates to the use of an agent capable of modulating the expression of *sphingosine kinase* or modulating the activity of sphingosine kinase in the manufacture of a medicament for the modulation of cellular functional activity.

30

- 33 -

A further aspect of the present invention relates to the use of sphingosine kinase or *sphingosine kinase* in the manufacture of a medicament for the modulation of cellular functional activity.

- 5 Still yet another aspect of the present invention relates to agents for use in modulating *sphingosine kinase* expression or sphingosine kinase activity wherein said modulation results in modulation of cellular functional activity.

Another aspect of the present invention relates to sphingosine kinase or *sphingosine kinase*
10 for use in modulating cellular functional activity.

In a related aspect of the present invention, the mammal undergoing treatment may be a human or an animal in need of therapeutic or prophylactic treatment.

- 15 In yet another further aspect the present invention contemplates a pharmaceutical composition comprising *sphingosine kinase*, sphingosine kinase or an agent capable of modulating *sphingosine kinase* expression or sphingosine kinase activity together with one or more pharmaceutically acceptable carriers and/or diluents. *Sphingosine kinase*, sphingosine kinase or said agent are referred to as the active ingredients.

20

The pharmaceutical forms suitable for injectable use include sterile aqueous solutions (where water soluble) and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. In all cases the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of
25 manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity can be maintained, for example, by the use of a coating such as
30 licithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The preventions of the action of microorganisms can be brought

- 34 -

about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents

5 delaying absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by

10 incorporating the various sterilized active ingredient into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and the freeze-drying technique which yield a powder of the active ingredient plus any additional desired ingredient from

15 previously sterile-filtered solution thereof.

When *sphingosine kinase*, sphingosine kinase and sphingosine kinase modulators are suitably protected they may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or they may be enclosed in hard or soft shell gelatin

20 capsule, or they may be compressed into tablets, or they may be incorporated directly with the food of the diet. For oral therapeutic administration, the active compound may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations should contain at least 1% by weight of active compound. The percentage of

25 the compositions and preparations may, of course, be varied and may conveniently be between about 5 to about 80% of the weight of the unit. The amount of active compound in such therapeutically useful compositions is such that a suitable dosage will be obtained. Preferred compositions or preparations according to the present invention are prepared so that an oral dosage unit form contains between about 0.1 μ g and 2000 mg of active

30 compound.

- 35 -

The tablets, troches, pills, capsules and the like may also contain the following: A binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, 5 lactose or saccharin may be added or a flavouring agent such as peppermint, oil of wintergreen, or cherry flavouring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills, or capsules may be coated with shellac, sugar or both. A syrup or 10 elixir may contain the active compound, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavouring such as cherry or orange flavour. Of course, any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed. In addition, the active compound may be incorporated into sustained-release preparations and formulations.

15

Pharmaceutically acceptable carriers and/or diluents include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with 20 the active ingredient, use thereof in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.

It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to 25 physically discrete units suited as unitary dosages for the mammalian subjects to be treated; each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the novel dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active material and the particular 30 therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding

- 36 -

such an active material for the treatment of disease in living subjects having a diseased condition in which bodily health is impaired.

The principal active ingredient is compounded for convenient and effective administration
5 in effective amounts with a suitable pharmaceutically acceptable carrier in dosage unit form as hereinbefore disclosed. A unit dosage form can, for example, contain the principal active compound in amounts ranging from 0.5 μ g to about 2000 mg. Expressed in proportions, the active compound is generally present in from about 0.5 μ g to about 2000 mg/ml of carrier. In the case of compositions containing supplementary active ingredients,
10 the dosages are determined by reference to the usual dose and manner of administration of the said ingredients.

The pharmaceutical composition may also comprise genetic molecules such as a vector capable of transfecting target cells where the vector carries a nucleic acid molecule capable
15 of expressing *sphingosine kinase*, modulating *sphingosine kinase* expression or sphingosine kinase activity. The vector may, for example, be a viral vector.

Sphingosine kinase can also be utilised to create gene knockout models in either cells or animals, which knocked out gene is the sphingosine kinase gene expressed by said cells or
20 animals. Accordingly in another aspect the present invention should be understood to extend to methods of creating sphingosine kinase gene cell or animal knockout models wherein sphingosine kinase has been utilised to facilitate knocking out of the endogenous sphingosine kinase gene of said cell or animal, and to the knockout models produced therefrom.

25

Still another aspect of the present invention is directed to antibodies to sphingosine kinase including catalytic antibodies. Such antibodies may be monoclonal or polyclonal and may be selected from naturally occurring antibodies to sphingosine kinase or may be specifically raised to sphingosine kinase. In the case of the latter, sphingosine kinase may first need to
30 be associated with a carrier molecule. The antibodies and/or recombinant sphingosine kinase of the present invention are particularly useful as therapeutic or diagnostic agents.

- 37 -

Alternatively, fragments of antibodies may be used such as Fab fragments. Furthermore, the present invention extends to recombinant and synthetic antibodies and to antibody hybrids. A "synthetic antibody" is considered herein to include fragments and hybrids of antibodies. The antibodies of this aspect of the present invention are particularly useful for immunotherapy and may also be used as a diagnostic tool, for example, for monitoring the program of a therapeutic regime.

For example, sphingosine kinase can be used to screen for naturally occurring antibodies to sphingosine kinase. These may occur, for example in some inflammatory disorders.

10

For example, specific antibodies can be used to screen for sphingosine kinase proteins. The latter would be important, for example, as a means for screening for levels of sphingosine kinase in a cell extract or other biological fluid or purifying sphingosine kinase made by recombinant means from culture supernatant fluid. Techniques for the assays contemplated herein are known in the art and include, for example, sandwich assays, ELISA and flow cytometry.

It is within the scope of this invention to include any second antibodies (monoclonal, polyclonal or fragments of antibodies) directed to the first mentioned antibodies discussed above. Both the first and second antibodies may be used in detection assays or a first antibody may be used with a commercially available anti-immunoglobulin antibody. An antibody as contemplated herein includes any antibody specific to any region of sphingosine kinase.

Both polyclonal and monoclonal antibodies are obtainable by immunization with the protein or peptide derivatives and either type is utilizable for immunoassays. The methods of obtaining both types of sera are well known in the art. Polyclonal sera are less preferred but are relatively easily prepared by injection of a suitable laboratory animal with an effective amount of sphingosine kinase, or antigenic parts thereof, collecting serum from the animal, and isolating specific sera by any of the known immunoadsorbent techniques. Although antibodies produced by this method are utilizable in virtually any type of

- 38 -

immunoassay, they are generally less favoured because of the potential heterogeneity of the product.

The use of monoclonal antibodies in an immunoassay is particularly preferred because of
5 the ability to produce them in large quantities and the homogeneity of the product. The
preparation of hybridoma cell lines for monoclonal antibody production derived by fusing
an immortal cell line and lymphocytes sensitized against the immunogenic preparation can
be done by techniques which are well known to those who are skilled in the art. (See, for
example Douillard and Hoffman, Basic Facts about Hybridomas, in *Compendium of*
10 *Immunology* Vol II, ed. by Schwartz, 1981; Kohler and Milstein, *Nature* 256: 495-499,
1975; *European Journal of Immunology* 6: 511-519, 1976).

In another aspect of the present invention, the molecules of the present invention are also
useful as screening targets for use in applications such as the diagnosis of disorders which
15 are regulated by sphingosine kinase.

Yet another aspect of the present invention contemplates a method for detecting
sphingosine kinase or *sphingosine kinase* mRNA in a biological sample from a subject said
method comprising contacting said biological sample with an antibody specific for
20 sphingosine kinase or *sphingosine kinase* mRNA or its derivatives or homologs for a time
and under conditions sufficient for an antibody-sphingosine kinase or antibody-sphingosine
kinase mRNA complex to form, and then detecting said complex.

The presence of sphingosine kinase may be determined in a number of ways such as by
25 Western blotting, ELISA or flow cytometry procedures. Sphingosine kinase mRNA may
be detected, for example, by *in situ* hybridization or Northern blotting. These, of course,
include both single-site and two-site or "sandwich" assays of the non-competitive types, as
well as in the traditional competitive binding assays. These assays also include direct
binding of a labelled antibody to a target.

30

- 39 -

Sandwich assays are among the most useful and commonly used assays and are favoured for use in the present invention. A number of variations of the sandwich assay technique exist, and all are intended to be encompassed by the present invention. Briefly, in a typical forward assay, an unlabelled antibody is immobilized on a solid substrate and the sample to
5 be tested brought into contact with the bound molecule. After a suitable period of incubation, for a period of time sufficient to allow formation of an antibody-antigen complex, a second antibody specific to the antigen, labelled with a reporter molecule capable of producing a detectable signal is then added and incubated, allowing time sufficient for the formation of another complex of antibody-antigen-labelled antibody. Any
10 unreacted material is washed away, and the presence of the antigen is determined by observation of a signal produced by the reporter molecule. The results may either be qualitative, by simple observation of the visible signal, or may be quantitated by comparing with a control sample containing known amounts of hapten. Variations on the forward assay include a simultaneous assay, in which both sample and labelled antibody are added
15 simultaneously to the bound antibody. These techniques are well known to those skilled in the art, including any minor variations as will be readily apparent. In accordance with the present invention the sample is one which might contain sphingosine kinase including cell extract, tissue biopsy or possibly serum, saliva, mucosal secretions, lymph, tissue fluid and respiratory fluid. The sample is, therefore, generally a biological sample comprising
20 biological fluid but also extends to fermentation fluid and supernatant fluid such as from a cell culture.

In the typical forward sandwich assay, a first antibody having specificity for the sphingosine kinase or antigenic parts thereof, is either covalently or passively bound to a
25 solid surface. The solid surface is typically glass or a polymer, the most commonly used polymers being cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene. The solid supports may be in the form of tubes, beads, discs of microplates, or any other surface suitable for conducting an immunoassay. The binding processes are well-known in the art and generally consist of cross-linking covalently binding or
30 physically adsorbing, the polymer-antibody complex is washed in preparation for the test sample. An aliquot of the sample to be tested is then added to the solid phase complex and

- 40 -

incubated for a period of time sufficient (e.g. 2-40 minutes) and under suitable conditions (e.g. 25°C) to allow binding of any subunit present in the antibody. Following the incubation period, the antibody subunit solid phase is washed and dried and incubated with a second antibody specific for a portion of the hapten. The second antibody is linked to a
5 reporter molecule which is used to indicate the binding of the second antibody to the hapten.

An alternative method involves immobilizing the target molecules in the biological sample and then exposing the immobilized target to specific antibody which may or may not be
10 labelled with a reporter molecule. Depending on the amount of target and the strength of the reporter molecule signal, a bound target may be detectable by direct labelling with the antibody. Alternatively, a second labelled antibody, specific to the first antibody is exposed to the target-first antibody complex to form a target-first antibody-second antibody tertiary complex. The complex is detected by the signal emitted by the reporter molecule.

15

By "reporter molecule" as used in the present specification, is meant a molecule which, by its chemical nature, provides an analytically identifiable signal which allows the detection of antigen-bound antibody. Detection may be either qualitative or quantitative. The most commonly used reporter molecules in this type of assay are either enzymes, fluorophores or
20 radionuclide containing molecules (i.e. radioisotopes) and chemiluminescent molecules.

In the case of an enzyme immunoassay, an enzyme is conjugated to the second antibody, generally by means of glutaraldehyde or periodate. As will be readily recognized, however, a wide variety of different conjugation techniques exist, which are readily available to the
25 skilled artisan. Commonly used enzymes include horseradish peroxidase, glucose oxidase, beta-galactosidase and alkaline phosphatase, amongst others. The substrates to be used with the specific enzymes are generally chosen for the production, upon hydrolysis by the corresponding enzyme, of a detectable color change. Examples of suitable enzymes include alkaline phosphatase and peroxidase. It is also possible to employ fluorogenic
30 substrates, which yield a fluorescent product rather than the chromogenic substrates noted above. In all cases, the enzyme-labelled antibody is added to the first antibody hapten

- 41 -

complex, allowed to bind, and then the excess reagent is washed away. A solution containing the appropriate substrate is then added to the complex of antibody-antigen-antibody. The substrate will react with the enzyme linked to the second antibody, giving a qualitative visual signal, which may be further quantitated, usually spectrophotometrically, to give an indication of the amount of hapten which was present in the sample. "Reporter molecule" also extends to use of cell agglutination or inhibition of agglutination such as red blood cells on latex beads, and the like.

Alternately, fluorescent compounds, such as fluorecein and rhodamine, may be chemically coupled to antibodies without altering their binding capacity. When activated by illumination with light of a particular wavelength, the fluorochrome-labelled antibody adsorbs the light energy, inducing a state to excitability in the molecule, followed by emission of the light at a characteristic color visually detectable with a light microscope. As in the EIA, the fluorescent labelled antibody is allowed to bind to the first antibody-hapten complex. After washing off the unbound reagent, the remaining tertiary complex is then exposed to the light of the appropriate wavelength the fluorescence observed indicates the presence of the hapten of interest. Immunofluorescence and EIA techniques are both very well established in the art and are particularly preferred for the present method. However, other reporter molecules, such as radioisotope, chemiluminescent or bioluminescent molecules, may also be employed.

The present invention also contemplates genetic assays such as involving PCR analysis to detect *sphingosine kinase* or its derivatives.

Further features of the present invention are more fully described in the following non-limiting examples.

EXAMPLE 1

PURIFICATION AND CLONING OF HUMAN SPHINGOSINE KINASE - EXPERIMENTAL PROCEDURES

5 *Materials*

D-erythro-Sphingosine, *D-erythro*-dihydrosphingosine, *DL-threo*-dihydrosphingosine, *N,N*-dimethylsphingosine, *N*-acetylsphingosine (C_2 -ceramide), S1P and Fumosin B1 were purchased from Biomol Research Laboratories Inc. (Plymouth Meeting, PA). Phytosphingosine, L- α -phosphatidic acid, L- α -phosphatidylinositol, L- α -
10 phosphatidylserine, L- α -phosphatidylcholine, L- α -phosphatidylethanolamine, 1,2-dioctanoyl-sn-glycerol, 1,2-dioleoyl-sn-glycerol, ATP, calmodulin, glutathione and bovine serum albumin (BSA) were from Sigma. *N,N,N*-trimethylsphingosine and ADP were purchased from Calbiochem (Band Soden, Germany), [$\gamma^{32}P$]ATP from Geneworks (Adelaide, South Australia), TNF α from R&D Systems Inc. (Minneapolis, MN), and
15 isopropyl- β -D-thiogalactoside (IPTG) from Promega (Madison, WI). Prepacked Mono-Q, Superose 75 and HiTrap-Q columns, Q Sepharose fast flow, calmodulin Sepharose 4B, glutathione Sepharose 4B, thrombin and gel filtration molecular mass protein standards were from Amersham Pharmacia Biotech. SDS-PAGE molecular mass protein standards, silver stain plus kit, Coomassie Brilliant Blue R250 and Coomassie protein reagent were
20 from Bio-Rad. Centricon concentrators were purchased from Amicon Inc. (Beverly, MA) and BCA protein reagent was from Pierce Chemical Company (Rockford, IL).

Sphingosine kinase enzyme assay

Sphingosine kinase activity was routinely determined using *D-erythro*-sphingosine and
25 [$\gamma^{32}P$]ATP as substrates, essentially as previously described (Olivera *et al.*, 1998) with some modifications. Briefly, assays were performed by incubating samples at 37°C for 30 min with sphingosine (100 μ M stock dissolved in 5% Triton X-100) and [$\gamma^{32}P$]ATP (1 mM; 10 μ Ci/ml) in assay buffer containing 100 mM Tris/HCl (pH 7.4), 10 mM MgCl₂, 10% (v/v) glycerol, 1 mM dithiothreitol, 1 mM EGTA, 1 mM Na₃VO₄, 15mM NaF, 0.5
30 mM 4-deoxypyridoxine in a total volume of 100 μ l. Reactions were terminated and sphingosine-1-phosphate extracted by the addition of 700 μ l of chloroform/methanol/HCl

(100:200:1, v/v), followed by vigorous mixing, addition of 200 μ l of chloroform and 200 μ l of 2 M KCl, and phase separation by centrifugation. The labeled S1P in the organic phase was isolated by TLC on Silica Gel 60 with 1-butanol/ethanol/acetic acid/water (8:2:1:2, v/v) and quantitated by phosphorimager (Molecular Dynamics, Sunnyvale, CA). One unit
5 (U) of activity is defined as 1 pmol of S1P formed per minute.

Purification of sphingosine kinase from human placenta

Sphingosine kinase was purified from 1240 g of human placenta (4 placentas), with all steps performed at 4°C. The placentas were diced, washed in buffer A (25 mM Tris/HCl
10 buffer, pH 7.4 containing 10% (v/v) glycerol, 0.05% Triton X-100 and 1 mM dithiothreitol), transferred to 1.5 L of fresh buffer A containing a protease inhibitor cocktail (Complete™; Boehringer Mannheim) (buffer B), and minced in a Waring blender. The resultant homogenate was stored on ice for 30 min to enhance enzyme extraction, and the soluble fraction of the homogenate then isolated by centrifugation at 17 000 g for 60 min.
15 This preparation was then fractionated by $(\text{NH}_4)_2\text{SO}_4$ precipitation by the addition of solid $(\text{NH}_4)_2\text{SO}_4$ at pH 7.4 and collection of the precipitated proteins by centrifugation (17 000 g, 30 min). The 25-35%-saturated $(\text{NH}_4)_2\text{SO}_4$ fraction was then redissolved in a buffer B, desalted by extensive dialysis against this same buffer, and centrifuged (17 000 g, 30 min) to remove insoluble material. All subsequent chromatographic steps were performed using
20 a FPLC system (Pharmacia Biotech) at 4°C.

The dialysed $(\text{NH}_4)_2\text{SO}_4$ fraction was applied to a Q-Sepharose fast flow column (50 mm diameter, 250 ml bed volume) pre-equilibrated with buffer A at a flow rate of 7 ml/min. Sphingosine kinase activity was eluted with a NaCl gradient of 0 to 1M in buffer A and
25 collected in 10 ml fractions. Fractions containing highest SK1 activity were then combined, and CaCl_2 and NaCl added to give final concentrations of 4 mM and 250 mM, respectively. This pooled extract was then applied to a calmodulin-Sepharose 4B column (16 mm diameter, 10 ml bed volume), pre-equilibrated with buffer A containing 2 mM CaCl_2 , at a flow rate of 1 ml/min. The column was then washed with several column
30 volumes of equilibration buffer, followed by buffer A containing 4 mM EGTA, and then SKI eluted with buffer A containing 4 mM EGTA and 1 M NaCl. The fractions containing

- 44 -

highest sphingosine kinase activity were pooled, desalted on a Sephadex G-25 column, and applied at a flow rate of 1 ml/min to a Mono-Q column (5 mm diameter, 1 ml bed volume) pre-equilibrated with buffer A. Sphingosine kinase activity was eluted with a NaCl gradient to 0 to 1M in buffer A. NaCl (to 500 mM) was immediately added to the fractions (1 ml) collected to stabilise enzyme activity. The Mono-Q fractions containing highest sphingosine kinase activity were combined and desalted on a Sephadex G-25 column. ATP and MgCl₂ were then added to the pooled fractions to a final concentrations of 1 mM and 5 mM, respectively, before reapplication at a flow rate of 1 ml/min to the Mono-Q column pre-equilibrated with buffer A containing 1 mM ATP and 5 mM MgCl₂. Sphingosine kinase activity was eluted with a NaCl gradient of 0 to 1M in the equilibration buffer. Again, NaCl (to 500 mM) was immediately added to the fractions (1 ml) collected to stabilise enzyme activity. The ATP-Mono-Q fractions containing highest sphingosine kinase activity were pooled and concentrated 10-fold to a final volume of 200 µl in a Centricon-10 concentrator and applied at a flow rate of 0.4 ml/min to a Superdex 75 column (10 mm diameter, 20 ml bed volume) pre-equilibrated with buffer A containing 500 mM NaCl. Sphingosine kinase activity was eluted with the same buffer and 0.4 ml fractions collected. The molecular mass of the enzyme was estimated from this column by comparison to the elution volumes of ribonuclease A, chymotrypsinogen A, ovalbumin and BSA.

Cloning of human sphingosine kinase

The human sphingosine kinase (hSK) was amplified from a HUVEC λ Zap cDNA library using PCR primers derived from human EST sequences (GenBank™ accession numbers D31133, W63556, AA026479, AA232791, AA081152, AI769914 and AI769914) aligned to the murine sphingosine kinases (Olivera *et al.*, 1998). These primers, spanning a central SacII site (P1, 5'-CGGAATTCCCAGTCGGCCGCGGTA-3' [<400>3] and P2, 5'-TAGAATTCTACCGCGGCCGACTGGCT-3' [<400>4]), were used in combination with T3 and T7 primers to generate two overlapping PCR products of 669 bp and 550 bp that represented the 5' and 3' ends of hSK, respectively. These two PCR products were then separately cloned into pGEM4Z. A 584 bp SacII fragment from the 5' hSK PCR clone was then sub-cloned in the correct orientation into the SacII site of the 3' hSK PCR clone, to

generate a 1130 bp partial hSK cDNA clone. A full length clone encoding hSK was then generated by sub-cloning a 120 bp *EcoRI/StuI* fragment from the 669 bp 5' hSK clone into this pGEM4Z-1130 bp clone digested with *EcoRI/StuI*. Sequencing the cDNA clone in both directions verified the integrity of the hSK cDNA sequence.

5

For mammalian cell expression the hSK cDNA was FLAG epitope tagged at the 3'-end by PFU polymerase PCR with oligonucleotide primers T7 and 5'-

TAGAATTCACTTGTCATCGTCGTCCTTGTAAGCTTAAGGGCTCTTCTGGCGGT-3' [$<400>5$]. This FLAG-tagged hSK cDNA was then cloned into pCDNA3 by digestion

10 with *EcoRI*. The orientation was determined by restriction analysis and sequencing verified the integrity of the hSK-FLAG cDNA sequence. For bacterial expression, the full length hSK cDNA was sub-cloned into pGEX4T2. The pGEM4Z-hSK clone was digested with *BamHI* and blunted with 3U PFU polymerase in 1 x PFU buffer, 50 μ M dNTP's at 72°C for 30 minutes. The 1163 bp hSK cDNA was gel purified following digestion with *SaII* and
15 the blunt/*SaII* fragment was then ligated to pGEX4T2 *SmaI/XhoI*.

Sphingosine kinase amino acid sequence analysis

The human sphingosine kinase amino acid sequence was searched against non-redundant amino acid and nucleotide sequence databases at the Australian National Genome

20 Information Service using the blastp and tblastn algorithms (Altschul *et al.*, 1990).

Cell culture

Human umbilical vein endothelial cells (HUVEC) were isolated as previously described (Wall *et al.*, 1978) and cultured on gelatin-coated culture flasks in medium M199 with

25 Earle's salts supplemented with 20% fetal calf serum, 25 μ g/ml endothelial growth supplement (Collaborative Research) and 25 μ g/ml heparin. The cells were passaged three times and grown to 80% confluency before treatment and harvesting. Human embryonic kidney cells (HEK293, ATCC CRL-1573) cells were cultured on Dulbecco's modified Eagle's medium containing 10% fetal calf serum, 2 mM glutamine, 0.2% (w/v) sodium
30 bicarbonate, penicillin (1.2 mg/ml), and gentamycin (1.6 mg/ml). HEK293 cells were transiently transfected using the calcium phosphate precipitation method (Graham & van

- 46 -

der Eb, 1973). Treatment of HUVEC and HEK293 cells with $\text{TNF}\alpha$ (1 ng/ml) was performed as previously described (Xia *et al.*, 1998).

EXAMPLE 2

5 **EXPRESSION AND ISOLATION OF RECOMBINANT HUMAN SPHINGOSINE KINASE FROM *E. COLI* - EXPERIMENTAL PROCEDURE**

The full length SPHK cDNA cloned into pGEX4T2 was transformed into *E. coli* BL21. Overnight cultures (100 ml) of transformed isolates were grown with shaking (200 rpm) at 10 30°C in Superbroth (20 g/L glucose, 35 g/L tryptone, 20 g/L yeast extract, 5 g/L NaCl, pH 7.5) medium containing ampicillin (100 mg/L). The cultures were diluted 1:20 in fresh medium and grown at 30°C with shaking to an OD_{600} of 0.6-0.7. Expression of the glutathione-s-transferase (GST)-coupled sphingosine kinase (GST-SK) was then induced by addition of 0.1 mM isopropyl- β -D-thiogalactoside and further incubation of the cultures 15 at 30°C for 3 h. After this time the bacterial cells were then harvested by centrifugation at 6,000 g for 20 min at 4°C and resuspended in 20 ml of buffer B containing 250 mM NaCl. the cells were then lysed with lysozyme at a final concentration of 0.3 mg/ml for 15 min at 25°C followed by sonication, consisting of three cycles of 20s ultrasonic pulses followed by one minute cooling. The lysate was then clarified by centrifugation at 50,000 g for 45 20 min at 4°C, followed by filtrating through 0.22 μm filters. To be filtered supernatant was then incubated with 0.2 volumes of 50% (w/v) glutathione-Sepharose 4B (Pharmacia) that was washed and pro-equilibrated with buffer B, for 60 min at 4°C with constant mixing. After this time the mixture was poured into a glass chromatography column (10 mm diam.) and the beads (with bound GST-SK) washed with 10 column volumes of buffer B at 4°C. 25 The GST-SK was then eluted from the column in 10 ml of buffer B containing 10 mM reduced glutathione. Cleavage of the GST away from sphingosine kinase was then performed by incubation with 20 μg (30 N.I.H. units) thrombin (Pharmacia) for 3h at 25°C. The released sphingosine kinase was then purified by application of the cleavage mix to a calmodulin-Sepharose column and then a Mono-Q anion exchange column for the 30 purification of the sphingosine kinase from human placenta. These columns resulted in purification of the recombinant sphingosine kinase to homogeneity.

- 47 -

EXAMPLE 3

CHARACTERISATION OF SPHINGOSINE KINASES - EXPERIMENTAL PROCEDURES

5 The effect of pH on the activity of the isolated sphingosine kinases was determined over the pH range 4.0 to 11.0 in 50 mM buffers (sodium acetate, pH 4.0-5.0; Mes, pH 6.0-7.0; Hepes, pH 7.0-8.2; Tris/HCl, pH 8.2-10.0; Caps, pH 10.0-11.0) at 37°C. pH stability was determined by assaying the residual activity after pre-incubation of the enzymes in the same buffers for 5h at 4°C. Similarly, thermal stabilities were determined by assaying the
10 residual activity after pre-incubation of the enzymes at various temperatures (4-80°C) for 30 min at pH 7.4 (50mM Tris/HCl containing 10% glycerol, 0.5 M NaCl and 0.05% Triton X-100). Substrate kinetics were analysed using Michaelis-Menten kinetics with a weighted non-linear regression program (Easterby, 1996). Since sphingosine and its analogues were added to the enzyme assays in mixed micelles with Triton X-100, where
15 they exhibit surface dilution kinetics (Buehrer and Bell, 1992), all K_m and K_i values obtained for these molecules were expressed as mol % of Triton X-100, rather than as bulk solution concentrations. For assays to determine the effect of calcium/calmodulin on sphingosine kinase activity, calcium and calmodulin were added to the standard assay mixtures containing 20 nM of isolated sphingosine kinase at final concentrations of 4 mM and 0.6
20 μ M, respectively.

EXAMPLE 4

OTHER ANALYTICAL METHODS

25 Protein was determined using either the Coomassie Brilliant Blue (Bradford *et al.*, 1976) or Bicinchoninic acid (Smith *et al.*, 1985) reagents using BSA as standard. In some cases protein estimations were performed after concentration and removal of detergent by precipitation (Wessel and Flügge, 1984) to increase the sensitivity and accuracy of the determinations. SDS-PAGE was performed according to the method of Laemmli (1970)
30 using 12% acrylamide gels. Protein bands on gels were visualised with either Coomassie Brilliant Blue R250 or silver staining. Molecular mass was estimated by comparison to the

- 48 -

electrophoretic mobility of myosin, β -galactosidase, BSA, ovalbumin, carbonic anhydrase, soybean trypsin inhibitor, lysozyme and aprotinin.

EXAMPLE 5

5 PURIFICATION OF HUMAN SPHINGOSINE KINASE - RESULTS

Just over half of the total sphingosine kinase activity in human placenta was present in the cytosol after tissue homogenisation (Table 3). The purification of sphingosine kinase from human placenta is summarised in Table 4. The soluble fraction from the homogenate of
10 four human placentae was initially subjected to ammonium sulphate precipitation. This resulted in a remarkably good purification of sphingosine kinase (33-fold), which precipitated in the 25-35% saturated ammonium sulphate fraction. For anion exchange chromatography the ammonium sulphate fraction was rapidly desalted through the use of Sephadex G25 column and the desalted fraction loaded immediately onto a Q Sepharose FF
15 column. The speed of this desalting step appeared critical since the sphingosine kinase activity appeared very unstable at NaCl concentrations below about 0.2 M, meaning slower desalting steps, such as dialysis, resulted in substantial losses of enzyme activity. Application of a NaCl gradient of 0 to 1 M to the Q Sepharose FF column resulted in two peaks of sphingosine kinase activity, eluting at approximately 0.15 M and 0.6 M NaCl, and
20 designated SK1 and SK2, respectively (Fig. 2). For this study SK1 was selected for further purification due to its greater abundance and stability; SK2 activity appeared very unstable and, unlike SK1, could not be stabilised by the addition of 0.5M NaCl, 10% glycerol and 0.05% Triton X-100. SK1 was also chosen since it appeared to be the isoform present in HUVEC, as discussed later.

25

Fractions from Q Sepharose FF column containing SK1 were then affinity purified by application to a calmodulin-Sepharose 4B column in the presence of 4mM CaCl_2 , and elution of SK1 performed with EGTA and NaCl, resulting in further substantial purification (38-fold) and high enzyme yields. SK1 could not be eluted from the
30 calmodulin Sepharose 4B column with EGTA alone, indicating an unusual association of the enzyme with this affinity matrix. The active fractions that eluted from the calmodulin

- 49 -

Sepharose 4B column were then desalted and applied to two subsequent steps of analytical anion exchange chromatography on a Mono Q column, with the second step performed in the presence of 1 mM ATP and 5mM MgCl₂ (Fig. 3). The active fractions resulting from these anion exchange steps were then applied to gel filtration chromatography with a Superdex 75 column as a final purification step. SK1 eluted from this column as a single peak with a molecule mass corresponding to 44 kDa. Analysis of the active fraction from this final column by SDS-PAGE with silver staining (Fig. 4) revealed a single band of molecular mass 45kDa, indicating a homogenous protein that has been purified over a million-fold from the original placenta extract with remarkably good yield of 7% of the original sphingosine kinase activity (Table 4). This is the first sphingosine kinase to be purified to homogeneity from a human source.

EXAMPLE 6

SPHINGOSINE KINASE ISOFORMS IN HUVEC - RESULTS

Since two sphingosine kinase activities were identified in human placenta (Fig 2) we examined the multiplicity of this enzyme activity in HUVEC by the use of preparative anion exchange columns. In contrast to other human tissues and cells, application of HUVEC extracts to these columns resulted in the appearance of only a single sphingosine kinase peak that eluted at the same point as the human placenta SK1 (Fig. 5). Similarly, only a single sphingosine kinase peak eluted after application of HUVEC extracts in which sphingosine kinase activity had been stimulated by 10 min treatment of HUVEC with TNF α (Xia *et al.*, 1999). These results would indicate that SK1, the human placenta sphingosine kinase isolated in this study, is probably the main isoform found in HUVEC, and that TNF α treatment results in an increase in the activity of this enzyme, rather than the activation of another, otherwise latent, isoform.

- 50 -

EXAMPLE 7**CLONING OF HUMAN SPHINGOSINE KINASE AND TRANSIENT
EXPRESSION IN HEK293 CELLS - RESULTS**

5 A human sphingosine kinase cDNA was generated from a HUVEC λ Zap library using primers designed from human ESTs aligned with the published murine sphingosine kinase sequence (Kohama *et al.*, 1998). The cloning strategy is shown in Figure 6 (prov). The cDNA has an apparent open reading frame coding for 384 amino acids (Fig. 7). it should be noted that the sequence lacked a recognisable Kozak consensus motif raising the possibility that the actual initiation sequence may not be included in this cDNA. The sphingosine kinase cDNA encodes for a protein (hSK) with a predicted isoelectric point of 6.64 and a molecular mass of 42,550 kDa, consistent with the molecular mass determined for the purified human placenta sphingosine kinase (SK1). Subcloning into pcDNA3 and transient expression of hSK in HEK293 cells resulted in a 3200-fold increase in sphingosine kinase activity in these cells (Fig. 8), compared with untransfected HEK293 cells or HEK293 cells transfected with empty vector, indicating that the generated hSK cDNA encodes a genuine sphingosine kinase. Interestingly, although hSK-transfected HEK293 cells had 3200-fold higher levels of sphingosine kinase activity, treatment of these cells with TNF α resulted in a rapid (10 min) increase in sphingosine kinase activity by a similar proportion (approximately 2-fold) to that seen in untransfected HEK293 cells (Fig. 8) (Xia *et al.*, 1998). This indicates the high levels of over-expressed sphingosine kinase are not saturating the TNF α mediated activation mechanism in these cells.

EXAMPLE 8**25 HUMAN SPHINGOSINE KINASE ANALYSIS - RESULTS**

A search of the database shown hSK has a high amino acid sequence similarity (28 to 36% identity) to two recently identified *Saccharomyces cerevisiae* sphingosine kinases (Nagiec *et al.*, 1998) and several other ESTs encoding putative sphingosine kinase proteins from
30 *Schizosaccharomyces pombe*, *Caenorhabditis elegans* and *Arabidopsis thaliana*. Multiple

sequence alignment of hSK with these homologues (Fig. 9) revealed several regions of highly conserved amino acids through the protein, but particularly towards the N-terminus.

A search of the domain structures of hSK sequence revealed three calcium/calmodulin binding motifs (Rhoads & Friedberg, 1997), one of the 1-8 14 type A ([FILVW]xxx{FAILVW}xx[FAILVW]xxxxx{FILVW} with net charge of +3 to +6) spanning residues 290 to 303, and two of the 1-8 14 type B ([FILVW]xxxxx{FAILVW}xxxxx[FILVW] with net charge of +2 to +4) that overlap between residues 134 to 153. Further analysis of the hSK sequence revealed a possible N-myristoylation site close to the N-terminus (at Gly⁵) that may be applicable if the protein is subject to proteolytic cleavage. Also identified were one putative casein kinase II (CKII) phosphorylation site (at Ser¹³⁰) and four putative PKC phosphorylation sites (at Thr⁵⁴, Ser¹⁸⁰, Thr²⁰⁵ and Ser³⁷¹) (Fig. 7). These putative phosphorylation sites are also found in both murine sphingosine kinase isoforms, although the mouse enzymes also display six more possible phosphorylation sites; four for PKC, and one each for CKII and protein kinase A, that do not occur in hSK.

A search of signalling domain sequences using the SMART search tool (Schultz *et al.*, 1998; Ponting *et al.*, 1999) revealed similarity in residues 16 to 153 of hSK to the putative diacylglycerol kinase (DGK) catalytic domain. hSK showed an overall 36% identity to the consensus sequence of the DGK catalytic domain family, and possessed 17 of the 24 very highly conserved amino acids of this domain. hSK, however, showed no homology with the proposed ATP binding motif of this domain (GxGxxGx_nK), although it should be noted that the applicability of this protein kinase ATP-binding site motif (Hanks *et al.*, 1988) to DGKs remains contentious (Schaap *et al.*, 1994); Sakane *et al.*, 1996; Masai *et al.*, 1993). Further sequence analysis of the human sphingosine kinases also failed to find regions showing any marked similarity to the proposed nucleotide-binding motifs found in other protein families (Saraste *et al.*, 1990; Walker *et al.*, 1982). Apart from the similarity to the DGK catalytic domain, hSK shows no similarity to other lipid binding enzymes, and does not appear to have any recognizable lipid binding domains, like PKC C2 or pleckstrin homology domains. There are also no other obvious regulatory domains, with the possible

- 52 -

exception of a proline-rich region at the C-terminus which has some similarity to SH3 binding domains (Ren *et al.*, 1993; Yu *et al.*, 1994).

EXAMPLE 9

5 EXPRESSION IN *E. COLI* AND ISOLATION OF RECOMBINANT SPHINGOSINE KINASE - RESULTS

The hSK cDNA was subcloned into the pGEX 4T-2 plasmid and hSK expressed as a glutathione s-transferase (GST) fusion protein in *E. coli* BL21 by IPTG induction (Fig. 10).
10 After the GST-hSK fusion protein was partially purified using glutathione Sepharose 4B, and the GST removed by thrombin cleavage, the hSK was further purified by subsequent elutions from calmodulin Sepharose and Mono-Q anion exchange columns. This resulted in high recovery of sphingosine kinase activity (greater than 70% of the originally induced activity), and an electrophoretically pure sphingosine kinase (Fig. 10). However, only low
15 protein yields of the recombinant enzyme could be obtained since a large proportion of the IPTG induced, thrombin-cleaved hSK protein did not bind to the calmodulin Sepharose column (Fig. 11). This non-binding form of hSK had no demonstrable catalytic activity, suggesting that it was incorrectly folded.

20 EXAMPLE 10

POST-TRANSLATIONAL MODIFICATION REQUIREMENT FOR SPHINGOSINE KINASE FUNCTIONAL ACTIVITY

To determine if post-translational modifications are required for activity of the native
25 sphingosine kinase, the native molecule has been compared to the recombinant enzyme produced in *E. coli* where such modifications would not occur. Specifically, the enzymes have been examined for differences in substrate affinity and accessibility. The premise for this study was that post-translational modifications may cause conformational changes in the structure of sphingosine kinase which may result in detectable changes in the physico-
30 chemical or catalytic properties of the enzyme. In summary, it was determined that

recombinantly produced sphingosine kinase retains its functional activity even in the absence of post-translational modification.

METHODS

5

Substrate specificity of the native and recombinant sphingosine kinases

Relative rates of phosphorylation of sphingosine by the native and recombinant sphingosine kinases were arbitrarily set at 100% and correspond to 2.65 kU and 7.43 kU of the native and recombinant sphingosine kinases, respective. The substrates examined were added to a
10 final concentration of 100 μ M in 0.25% (w/v) Triton X-100, and assayed under the standard assay conditions outlined earlier.

Substrate and inhibitor kinetics of the native and recombinant sphingosine kinases

Substrate kinetics were determined by supplying substrates over the concentration range of
15 0.5 to 200 μ M for sphingosine analogues, and 5 to 1000 μ M for ATP. Inhibition kinetics were determined by the use of inhibitors over a concentration range of 2 to 50 μ M (Table 5). In both cases the data were analysed by non-linear regression.

Thermal stabilities of the native and recombinant sphingosine kinases

20 Thermal stabilities of the native and recombinant sphingosine kinases were determined by assaying the residual activity remaining after preincubation of the enzymes at various temperatures (4 to 80°C) for 30 min at pH 7.4 (50mM Tris/HCl containing 10% glycerol, 0.5M NaCl and 0.05% Triton X-100). The original activities of the native and recombinant sphingosine kinases were arbitrarily set at 100% and correspond to 2.65 kU and 7.43 kU,
25 respectively.

pH stabilities of the native and recombinant sphingosine kinases

pH stabilities of the native and recombinant sphingosine kinases were determined by assaying the residual activity remaining after preincubation of the enzymes at various pH's
30 at 4°C for 5 hr. The original activities of the native and recombinant sphingosine kinases were arbitrarily set at 100% and correspond to 2.65 kU and 7.43 kU, respectively.

The effect of pH on activity of the native and recombinant sphingosine kinases

The effect of pH on the activity of the native and recombinant sphingosine kinases were determined by assaying the activity over the pH range of 4 to 11 in 50mM buffers (sodium acetate, pH 4.0-5.0; Mes, pH 6.0-7.0; Hepes, pH 7.0-8.2; Tris, pH 8.2-10.0; Caps, pH 10.0-11.0). The maximum activities of the native and recombinant sphingosine kinases were arbitrarily set at 100% and correspond to 2.65 kU and 7.43 kU, respectively.

Effect of metal ions on the activity of the native and recombinant sphingosine kinases

The effect of metal ions on the activity of the native and recombinant sphingosine kinases were determined by assaying the activity under standard conditions in the presence of various metal ions or EDTA at 10mM. The maximum activities of the native and recombinant sphingosine kinases were arbitrarily set at 100% and correspond to 2.65 kU and 7.43 kU, respectively.

Effect of phospholipids on the activity of the native and recombinant sphingosine kinases

The effect of various phospholipids on the activity of the native and recombinant sphingosine kinases were determined by assaying the activity under standard conditions in the presence of these phospholipids at 10 mol% of Triton X-100. The activities of the native and recombinant sphingosine kinases in the absence of phospholipids were arbitrarily set at 100% and correspond to 2.65 kU and 7.43 kU, respectively. PC, phosphatidylcholine; PS phosphatidylserine; PE, phosphatidylethanolamine; PI, phosphatidylinositol.

25 RESULTS

Maximum activity of the native and recombinant sphingosine kinases were observed at pH 7.4, with both enzymes showing greater than 60% of maximum activity in the pH range 6.8 to 7.4 (Fig. 12). Both sphingosine kinases retained more than 90% of the original activity after 5 h incubation at 4°C in the pH range 6 to 7.8 (Fig. 12), and at pH 7.4 in the presence of 10% glycerol, 0.5M NaCl and 0.05% Triton X-100, both enzymes were stable for 30

- 55 -

min at temperatures up to 37°C (Fig. 12). The enzymes were much less stable in buffers lacking glycerol, NaCl and Triton X-100 (data not shown), consistent with previous observations of the bovine brain and rat kidney sphingosine kinases (Louie *et al.*, 1976; Olivera *et al.*, 1998). Both human sphingosine kinases showed a requirement for divalent metal ions since the presence of EDTA in assays eliminated activity (Fig. 12). Like other sphingosine kinases examined (Louie *et al.*, 1976; Buehrer & Bell, 1992; 1993; Olivera *et al.*, 1998; Nagiec *et al.*, 1998), both human enzymes showed highest activity with Mg^{2+} , somewhat lower activity with Mn^{2+} , and only very low activity with Ca^{2+} . Other divalent metal ions examined, including Zn^{2+} , Cu^{2+} and Fe^{2+} , did not support sphingosine kinase activity (Fig. 12).

The native and recombinant sphingosine kinases have very similar, and narrow, substrate specificities (Fig. 13), with both showing greatest activity with the naturally occurring mammalian substrate D-erythro-sphingosine as well as D-erhthro-dihydrosphingosine. Low activity was also detected for both enzymes against phytosphingosine, while a range of other sphingosine derivatives and related molecules were not phosphorylated. These included DL-threo-dihydrosphingosine, N,N-dimethylsphingosine, N,N,N-trimethylsphingosine, N-acetylsphingosine (C_2 -ceramide), diacylglycerol (1,2-dioctanoyl-sn-glycerol and 1,2-dioleoyl-sn-glycerol), and phosphatidylinositol. Further analysis of the human sphingosine kinases with D-erythro-sphingosine as well as D-erhthro-dihydrosphingosine revealed Michaelis-Menten kinetics over the concentration range used (Fig. 13), with both isolated native and recombinant sphingosine kinases showing very similar kinetic properties and slightly higher affinity for D-erythro-sphingosine as well as D-erhthro-dihydrosphingosine (Table 5). Both enzymes also displayed similar kinetics when sphingosine was supplied as a sphingosine-BSA complex, although presentation of the substrate in this manner resulted in a lower k_{cat} values for both enzymes ($28\ s^{-1}$ and $39\ s^{-1}$ for the native and recombinant sphingosine kinases, respectively) compared to its presentation in Triton X-100 mixed micelles, as used for all the other assays performed in this study. Sphingosine supplied as a BSA complex K_m values of $16 \pm 4\ mM$ and $17 \pm 2\ mM$ for the native and recombinant sphingosine kinases, respectively. Both the native and

- 56 -

recombinant sphingosine kinases had the same affinity for ATP (K_m of approx. 80 mM (Table 5).

Both the native and recombinant sphingosine kinase were inhibited by DL-*threo*-
5 dihydrosphingosine, *N,N*-dimethylsphingosine and *N,N,N*-trimethylsphingosine (Fig. 13),
with all three of these molecules displaying competitive inhibition with respect to
sphingosine. Although the inhibition constants for these molecules were quite similar,
N,N,N-trimethylsphingosine gave slightly more efficient inhibition than DL-*threo*-
dihydrosphingosine, which was a marginally more efficient inhibitor than *N,N*-
10 dimethylsphingosine (Table 5).

ADP also showed weak competitive inhibition, with respect to ATP (Table 5). In all cases
remarkably similar inhibition constants were observed for the native and recombinant
sphingosine kinases (Table 5). No inhibition was seen with N-acetylsphingosine or
15 Fumisin B1, a ceramide synthase inhibitor.

The effect of calcium/calmodulin on sphingosine kinase activity was examined. Under the
assay conditions used, calcium/calmodulin had no effect on the activity of either the native
or recombinant human sphingosine kinases (data not shown). While this result indicates a
20 lack of sphingosine kinase activity regulation by calmodulin, the possibility remains that
calmodulin may be involved in some other function with sphingosine kinase, such as
regulating its subcellular localisation.

Stimulation of sphingosine kinase activity by acidic phospholipids was examined. The
25 addition of the neutral phospholipids phosphatidylcholine and phosphatidylethanolamine to
the enzyme assay mixture did not result in any detectable differences in human sphingosine
kinase activity, however, marked increases in activity (1.6 to 2-fold) were observed with
the acidic phospholipids phosphatidylserine, phosphatidylinositol and phosphatidic acid
(Fig. 14). Both the native and recombinant sphingosine kinases were activated in a similar
30 manner by these acidic phospholipids, with kinetic analyses revealing that all three

- 57 -

phospholipids caused an increase in the enzymes K_{cat} , while the K_m values remained unchanged.

Those skilled in the art will appreciate that the invention described herein is susceptible to
5 variations and modifications other than those specifically described. It is to be understood
that the invention includes all such variations and modifications. The invention also
includes all of the steps, features, compositions and compounds referred to or indicated in
this specification, individually or collectively, and any and all combinations of any two or
more of said steps or features.

Table 3 - Comparison of sphingosine kinase activity in human placenta with various animal tissues

Fresh animal tissues were washed and homogenized as described for the human placenta. The proportion of cytosolic sphingosine kinase activity was determined by comparison of the total activity in the homogenate to that from the ultracentrifugation supernatant (100,000 x g, 60 min). The specific activity of sphingosine kinase is expressed as pmol of SIP formed per minute (U) per g tissue.

	Specific activity (U/g tissue)	Cytosolic (%)
Human placenta	13	51
Rat kidney	28	63
Rat liver	19	37
Rat brain	13	52
Sheep kidney	38	58
Sheep liver	17	31
Sheep brain	16	63
Sheep spleen	9	34

Table 4 - Purification of sphingosine kinase from human placenta

Sphingosine kinase was purified from 1240 g of fresh human placenta (4 placentas). One unit (U) of sphingosine kinase activity is defined as 1 pmol of SIP formed from sphingosine and ATP per minute.

Step	Activity (U x 10 ³)	Protein (mg)	Specific Activity (U/mg)	Recovery (%)	Purification Fold
Soluble fraction of homogenate	7943	123600	58	100	
Ammonium sulphate (25-35%)	7723	3527	1966	97	33
Q Sepharose anion exchange	4048	1098	4597	63	79
Calmodulin Sepharose	3197	18.23	1.75 x 10 ⁵	40	3.0 x 10 ³
Mono Q anion exchange	1706	2.921	5.84 x 10 ⁵	21.5	1.0 x 10 ⁴
ATP- Mono Q anion exchange	1133	0.419	2.70 x 10 ⁶	14.3	4.6 x 10 ⁴
Superdex 75 gel filtration	549	0.008	6.64 x 10 ⁷	6.9	1.1 x 10 ⁶

Table 5 - Substrate and inhibition kinetics of the native and recombinant sphingosine kinases

Substrate kinetics were determined by supplying substrates over the concentration range of 0.5 to 200 μ M (0.0125 to 5 mol %) for sphingosine analogues, and 5 to 1000 μ M for ATP. Inhibition kinetics were determined by the use of inhibitors over a concentration range of 2 to 50 μ M (0.05 to 1.25 mol %) for sphingosine analogues and 0.1 to 5 mM for ADP. For comparison to previous studies, all K_m and K_i values for sphingosine and its derivatives are expressed as both bulk solution concentrations and mol % of Triton X-100, where Triton X-100 was present in all assays at a final concentration of 0.25% (w/v). All kinetic values and standard errors (Duggleby, 1981) were obtained from non-linear regression analysis (Easterby, 1996).

	Native SK	Recombinant SK
<i>SUBSTRATE KINETICS:</i>		
Sphingosine		
K_m (mol %)	0.35 ± 0.05	0.30 ± 0.07
K_m (μ M)	14 ± 2	12 ± 3
k_{cat} (S^{-1})	50	85
k_{cat} / K_m ($10^{-5} s^{-1} \cdot M^{-1}$)	36	71
Dihydrosphingosine		
K_m (mol %)	0.50 ± 0.05	0.48 ± 0.05
K_m (μ M)	20 ± 2	19 ± 2
k_{cat} (S^{-1})	35	76
k_{cat} / K_m ($10^{-5} s^{-1} \cdot M^{-1}$)	18	39
ATP		
K_m (μ M)	77 ± 11	86 ± 12
<i>INHIBITOR KINETICS:</i>		
<i>N,N</i> -dimethylsphingosine		
K_i (mol %)	0.20 ± 0.03	0.19 ± 0.02
K_i (μ M)	7.8 ± 1	7.5 ± 1
DL- <i>threo</i> -dihydrosphingosine		
K_i (mol %)	0.15 ± 0.02	0.14 ± 0.03
K_i (μ M)	5.9 ± 1	5.7 ± 1
<i>N,N,N</i> -trimethylsphingosine		
K_i (mol %)	0.12 ± 0.03	0.10 ± 0.02
K_i (μ M)	4.6 ± 1	3.8 ± 1
ADP		
K_i (mM)	1.1 ± 0.3	0.9 ± 0.2

BIBLIOGRAPHY

- Altschul, S.F., Gish, W., Miller, W., Meyer, E.W., and Lipman, D.J., (1990) *J. Mol. Biol.* **215**:403-410
- Alessenko, A.V., (1998) *Biochemistry* **63**:62-68
- Bonner *et al.*, (1973) *J. Mol. Biol.* **81**:123
- Bradford, M.M., (1976) *Anal. Biochem.* **72**:248-254
- Buehrer, B.M., and Bell, R.M., (1992) *J. Biol. Chem.* **267**:3154-3159
- Buehrer, B.M., and Bell, R.M., (1993) *Adv. Lipid Res.* **26**:59-67
- Buehrer, B.M., Bardes, E.S., and Bell, R.M., (1996) *Biochim. Biophys. Acta* **1303**:233-242
- Culliver, O., Pirianov, G., Kleuser, B., Vanek, P.G., Coso, O.A., Gutkind, J.S., and Spiegel, S., (1996) *Nature* **381**:800-803
- Douillard and Hoffman, Basic facts about hybridomas in Compendium of Immunology, Vol II ed. Schwartz (1981)
- Duggleby, R.G., (1981) *Anal Biochem.* **110**:9-18
- Easterby, J.S., (1996) Hyper 1.1s: Hyperbolic Regression Analysis of Enzyme Kinetic Data. Liverpool University, Liverpool
- Graham, F.L., and van der Eb, A.J., (1973) *Virology* **54**:536-539
- Hanks, S.K., Quinn, A.M., and Hunter, T., (1988) *Science* **241**:42-52

- 62 -

Igarashi, Y., (1997) *J. Biochem.* **122**:1080-1087

Kohama, T., Olivera, A., Edsall, L., Nagiec, M.M., Dickson, R. and Spiegel, S., (1998) *J. Biol. Chem.* **273**:23722-23728

Kohler and Milstein., (1975) *Nature* **256**:495-499

Laemmli, U.K., (1970) *Nature* **227**:680-685

Louie, D.D., Kisic, A., and Schroepfer, G.J., (1976) *J. Biol. Chem.* **251**:4557-4564

Masai, I., Okazaki, A., Hosoya, T., and Hotta, Y., (1993) *Proc. Natl. Acad. Sci. USA* **90**:11157-11161

Melendez, A., Floto, R.A., Gillooly, D.J., Harnett, M.M. and Allen, J.M., (1998) *J. Biol. Chem.* **273**:9393-9402

Meyer zu Heringdorf, D., van Koppen, C.J. and Jakobs, K.H., (1997) *FEBS Lett* **410**:34-38

Nagiec, M.M., Skrzypek, M., Nagiec, E.E., Lester, R.L., and Dickson, R.C., (1998) *J. Biol. Chem.* **273**:19437-19442

Olivera, A. and Spiegel, S., (1993) *Nature* **365**:557-560

Olivera, A., Kohama, T., Tu, Z., Milstein, S., and Spiegel, S., (1998) *J. Biol. Chem.* **273**:12576-12583

Ponting, C.P., Schultz, J., Milpetz., and Bork, P., (1999) *Nucleic Acids Res.* **27**:229-232

Ren, R., Mayer, B.J., Cicchetti, P., and Baltimore, D., (1993) *Science* **259**:1157-1161

- 63 -

Rhoads, A.R., and Friedberg, F., (1997) *FASEB J.* 11:331-340

Sakane, F., Lai, M., Wada, I., Imai, S., and Kohoh, H., (1996) *Biochem. J.* 318:583-590

Saraste, M., Sibbald, P.R., and Wittinghofer, A., (1990) *Trends Biochem. Sci.* 15:430-434

Schaap, D., van der Wal, J., and van Blitterswijk, W., (1994) *Biochem. J.* 304:661-662

Schultz, J., Milpetz, F., Bork, P., and Ponting, C.P., (1998) *Proc. Natl. Acad. Sci. USA* 95:5857-5864

Smith, P.K., Krohn, R.I., Hermanson, G.T., Mallia, A.K., Gartner, F.H., Provenzano, M.D., Fujimoto, E.K., Goeke, N.M., Olson, B.J., and Klenk, D.C., (1985) *Anal. Biochem.* 150:76-85

Spiegel, S., Culliver, O., Edsall, L., Kohama, T., Menzeleev, R., Olivera, A., Thomas, D., Tu, Z., Van Brocklyn, J. and Wang, F., (1998). *Biochemistry (Mosc)* 63:69-73

Walker, J.E., Saraste, M., Runswick, M.J., and Gray, N.J., (1982) *EMBO J.* 8:945-951

Wall, R.T., Harker, L.A., Quadracci, L.J., and Striker, G.E., (1978) *J. Cell. Physiol.* 96:203-213

Wessel, D., and Flügge, U.I., (1984) *Anal. Biochem.* 138:141-143

Xia, P., Gamble, J.R., Rye, K.-A., Wang, L., Hii, C.S.T., Cockerill, P., Khew-Goodall, Y., Bert, A.G., Barter, P.J. and Vadas, M.A., (1998) *Proc. Natl. Acad. Sci. USA* 95:14196-14201

Yu, H., Chen, J.K., Feng, S., Dalgarno, D.C., Brauer, A.W., and Schreiber, S.L., (1994) *Cell* 76:933-945

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. An isolated nucleic acid molecule or derivative or analogue thereof comprising a nucleotide sequence encoding or complementary to a sequence encoding a novel sphingosine kinase protein or a derivative or mimetic of said sphingosine kinase protein.
2. An isolated nucleic acid molecule according to claim 1 wherein said sphingosine kinase protein is a human sphingosine kinase protein.
3. An isolated nucleic acid molecule or derivative or analogue thereof comprising a nucleotide sequence encoding, or a nucleotide sequence complementary to a nucleotide sequence encoding, an amino acid sequence substantially as set forth in <400>2 or a derivative or mimetic thereof or having at least about 45% or greater similarity to at least 10 contiguous amino acids in <400>2.
4. An isolated nucleic acid molecule or derivative or analogue thereof comprising a nucleotide sequence substantially as set forth in <400>1 or a derivative thereof capable of hybridising to <400>1 under low stringency conditions.
5. An isolated nucleic acid molecule according to claim 4 which further encodes an amino acid sequence corresponding to an amino acid sequence set forth in <400>2 or a sequence having at least about 45% similarity to at least 10 contiguous amino acids in <400>2.
6. An isolated nucleic acid molecule according to claim 3 or 4 substantially as set forth in <400>1.
7. An isolated protein or derivative, analogue, chemical equivalent or mimetic thereof wherein said protein is a novel sphingosine kinase protein.

- 65 -

8. An isolated protein according to claim 7 wherein said sphingosine kinase protein is a human sphingosine kinase protein.
9. An isolated protein comprising an amino acid sequence substantially as set forth in <400> 2 or a derivative or mimetic thereof or a sequence having at least about 45% similarity to at least 10 contiguous amino acids in <400> 2 or a derivative, analogue, chemical equivalent or mimetic of said protein.
10. An isolated protein according to claim 9 encoded by a nucleotide sequence substantially as set forth in <400> 1 or a derivative or analogue thereof or capable of hybridising to <400> 1 under low stringency conditions or a derivative, analogue, chemical equivalent or mimetic of said protein.
11. An isolated protein according to claim 9 or 10 substantially as set forth in <400> 2.
12. A method of modulating expression of *sphingosine kinase*, in a subject, said method comprising contacting the *sphingosine kinase* gene with an effective amount of an agent for a time and under conditions sufficient to modulate expression of sphingosine kinase.
13. A method of modulating the functional activity of sphingosine kinase in a mammal, said method comprising administering to said mammal a modulating effective amount of an agent for a time and under conditions sufficient to increase or decrease sphingosine kinase activity.
14. A method of modulating cellular functional activity in a mammal said method comprising administering to said mammal an effective amount of an agent for a time and under conditions sufficient to modulate the expression of *sphingosine kinase* or sufficient to modulate the activity of sphingosine kinase.

- 66 -

15. A method of modulating cellular functional activity in a mammal said method comprising administering to said mammal an effective amount of a protein according to any one of claims 7-11 or a derivative, analogue, chemical equivalent or mimetic thereof for a time and under conditions sufficient to modulate the functional activity of said cell.
16. A method of modulating cellular functional activity in a mammal said method comprising administering to said mammal an effective amount of a nucleic acid molecule according to any one of claims 1-6 or a derivative, analogue, chemical equivalent or mimetic thereof for a time and under conditions sufficient to modulate the functional activity of said cell.
17. A method of modulating cellular functional activity in a mammal said method comprising administering to said mammal an effective amount of an agent for a time and under conditions sufficient to modulate the expression of *sphingosine kinase* or sufficient to modulate the activity of sphingosine kinase wherein said *sphingosine kinase* expression product or sphingosine kinase modulates the activity of said cell.
18. A method of treating a mammal said method comprising administering to said mammal an effective amount of an agent for a time and under conditions sufficient to modulate the expression of *sphingosine kinase* wherein said modulation results in modulation of cellular functional activity.
19. A method of treating a mammal said method comprising administering to said mammal an effective amount of an agent for a time and under conditions sufficient to modulate the activity of sphingosine kinase wherein said modulation results in modulation of cellular functional activity.

- 67 -

20. A method of treating a mammal said method comprising administering to said mammal an effective amount of a protein according to any one of claims 7-11 or a derivative, analogue, chemical equivalent or mimetic thereof for a time and under conditions sufficient to modulate cellular functional activity.
21. A method of treating a mammal said method comprising administering to said mammal an effective amount of a nucleic acid molecule according to any one of claims 1-6 or a derivative, analogue, chemical equivalent or mimetic thereof for a time and under conditions sufficient to modulate cellular functional activity.
22. Use of an agent capable of modulating the expression *sphingosine kinase* or a derivative, analogue, chemical equivalent or mimetic thereof in the manufacture of a medicament for the modulation of cellular functional activity.
23. Use of an agent capable of modulating the activity of sphingosine kinase or a derivative, analogue, chemical equivalent or mimetic thereof in the manufacture of a medicament for the modulation of cellular functional activity.
24. Use of sphingosine kinase or *sphingosine kinase* or a derivative, analogue, chemical equivalent or mimetic thereof in the manufacture of a medicament for the modulation of cellular functional activity.
25. An agent for use in modulating sphingosine kinase activity or a derivative, analogue chemical equivalent or mimetic thereof wherein modulating said sphingosine kinase activity modulates cellular functional activity.
26. An agent for use in modulating *sphingosine kinase* expression or a derivative, analogue, chemical equivalent or mimetic thereof wherein modulating expression of said *sphingosine kinase* modulates cellular functional activity.

- 68 -

27. Sphingosine kinase or *sphingosine kinase* or a derivative, analogue, chemical equivalent or mimetic thereof for use in modulating cellular functional activity.
28. A pharmaceutical composition comprising *sphingosine kinase*, sphingosine kinase or an agent capable of modulating *sphingosine kinase* or sphingosine kinase or derivative, homologue, analogue, chemical equivalent or mimetic thereof together with one or more pharmaceutically acceptable carriers and/or diluents.
29. An isolated antibody directed to the protein according to any one of claims 7-11.
30. An isolated antibody directed to the nucleic acid molecule according to any one of claims 1-6.
31. The antibody according to claim 29 or 30 wherein said antibody is a monoclonal antibody.
32. The antibody according to claim 29 or 30 wherein said antibody is a polyclonal antibody.
33. A method of diagnosing or monitoring a mammalian disease condition said method comprising screening for sphingosine kinase or *sphingosine kinase* in a biological sample isolated from said mammal.




Figure 1

Substitute Sheet
(Rule 26) RO/AU

2/21




Figure 2

3/21




Figure 3

Substitute Sheet
(Rule 26) RO/AU

4/21




Figure 4

Substitute Sheet
(Rule 26) RO/AU

5/21




Figure 5

Substitute Sheet
(Rule 26) RO/AU

6/21

Cloning of HUVEC SK




Figure 6




Figure 7a

Substitute Sheet
(Rule 26) RO/AU

1 M D P A G G P R G V L P R P C R V L V 19
1 gagccgcggtcaggttATGGATCCAGCGGGGGCGTGTCTCCGGGCCCTGCCGGTGTGGTG 75
20 L L N P R G G K A L Q L F R S H V Q P L L A E 44
76 CTGCTGAACCCGCGCGGCAAGGCAAGCCTTGACAGCTCTCCGGAGTCACGTGCAGCCCCCTTTGGCTGAG 150
45 A E I S F T L M L T E R R N H A R E L V R S E E L 69
151 GCTGAAATCTCCTTCACGCTGATGCTACCTGAGCGGGGAACACGCGGGAGCTGGTGGTTCGGAGGAGCTG 225
70 G R W D A L V V M S G D G L M H E V V N G L M E R 94
226 GGCCGCTGGGACGCTCTGGTGGTCATGTCTGGAGACGGGCTGATGCACGAGGTGGTGAACGGGCTCATGGAGCGG 300
95 P D W E T A I Q K P L C S L P A G S G N A L A A S 119
301 CCTGACTGGGAGACCGCCATCCAGAAGCCCCCTGTAGCCCTCCAGCAGGCTCTGGCAACGCGCTGGCAGCTTCC 375
120 L N H Y A G Y E Q V T N E D L L T N C T L L L C R 144
376 TTGAACCATTTATGCTGGCTATGAGCAGGTACCAATGAAGACCTCCTGACCAACTGCACGCTATGCTGTGCCGC 450
145 R L L S P M N L L S L H T A S G L R L F S V L S L 169
451 CGGCTGCTGCACCCATGAACCTGCTCTCTGCACACGGCTTCGGGGCTGGCCCTCTTCTCTGTGCTCAGCCTG 525
170 A W G F I A D V D L E S E K Y R R L G E M R F T L 194
526 GCCTGGGGCTTCATTGCTGATGTGGACCTAGAGAGTGAGAAGTATCGGCGTCTGGGGGAGATGGGCTTCACTCTG 600

Figure 7a(i)

9/21

```

195 G T F L R L A A L R T Y R G R L A Y L P V G R V G 219
601 GGCACCTTCCGTGGCTGGCAGCCCTGGCAGCTTACCGCGCCGACTGGCTTACCTCCCTGTAGGAAGAGTGGGT 675

220 S K T P A S P V V V Q Q G P V D A H L L V P L E E P 244
676 TCCAAGACACCTGCCTCCCCCGTTGGTCCAGCAGGGCCCGGTAGATGCACACCTTGTGCCACTGGAGGAGCCA 750

245 V P S H W T V V P D E D F V L L A L L H S H L G 269
751 GTGCCCCCTCACTGGACAGTGGTGCCCGACGAGGACTTGTGTCTAGTCCCTGGCAGCTGCTGCACCTCGCACCTGGGC 825

270 S E M F A A P M G R C A A G V M H L F Y V R A G V 294
826 AGTGAGATGTTTGTGCTGCACCCATGGGCGCTGTGCAGCTGGCGTCATGCTCTTCTACGTGCGGGGGGAGTG 900

295 S R A M L L R L F L A M E K G R H M E Y E C P Y L 319
901 TCTCGTGCCATGCTGTGGCCCTTCTCCCTGGCCATGGAGAAGGCAGGCATATGGAGTATGAATGCCCCCTACTTG 975

320 V Y V P V V A F R L E P K D G K G M F A V D G E L 344
976 GTATATGTGCCCCGTGGCTCGCTTCCGCTTGGAGCCCAAGGATGGAAAGGTATGTTTGCAGTGGATGGGGAATTG 1050

345 M V S E A V Q G Q V H P N Y F W M V S G C V E P P 369
1051 ATGGTTAGCGAGGCCGTGCAGGGCCAGGTGCACCCAACTACTTCTGGATGGTCAGCGGTTGCGTGGAGCCCCCG 1125

370 P S W K P Q Q M P P P E E P L . 384
1126 CCCAGCTGGAAGCCCCCAGCAGATGCCACCGCCAGAAGAGCCCTTatga 1173

```

Figure 7a(ii)




Figure 7b

11/21




Figure 8




Figure 9

hSK	1MDPAGGPRGVLP	PCRVLV	LLNP	GGK	KALQ	FRSHVQ	PL	LAAEAEIS
mSK1a	1MEPECPRGLLP	PCRVLV	LLNP	GGK	KALQ	FQSRVQ	PF	LEEAEIT
mSK1b	1	MWCCVL	FVVECP	RGLLP	PCRVLV	LLNP	GGK	KALQ	FQSRVQ
Yeast LCB4	206	NISSGT	VEE	ILEKSY	ENSK	RNSIL	VIIN	PHGGK	GTAKN
Yeast LCB5	252	DL...	VEE	ILKRSY	KNTR	NKSIF	VIIN	PHGGK	GTAKN
S. pombe	90	FCEY	LLDV	AYKGI	KRRSR	FIV	INPH	GGK
C. elegans	63	ENEQL	TSV	ILSR	KPP	QEQ	CRGN	LLVF	INP
Consensus	*R	...	**V	*NP	GGK	GKA	...*
									F...P.L...
hSK	112	SGNALAA	SL	NHYA	GYEQ	VTNED	LL	TNCT	LL
mSK1a	111	SGNALAA	SV	NHYA	GYEQ	VTNED	LL	LINCT	LL
mSK1b	118	SGNALAA	SV	NHYA	GYEQ	VTNED	LL	LINCT	LL
Yeast LCB4	325	SGNAM	SIS	CHWT	NNPS	YAAL	CLV	KSI
Yeast LCB5	368	SGNAM	SVS	CHWT	NNPS	YSTL	CL	IKSI
S. pombe	203	SGNA	FSYN	ATGQ	LKP	ALTAL	EIL	KGR
C. elegans	184	SGNGL	LC	SV	..LSKY	G	TKM	NEK	SVMER
Consensus		SGNA*	..S*	L	.*	M.....

Figure 9(i)

14/21

hSK	211AYLP.....	VGRVGSKTPASPVVVQQGPVD
mSK1a	210AYLP.....	VGTVASKRPAST.LVQKGPVD
mSK1b	217AYLP.....	VGTVASKRPAST.LVQKGPVD
Yeast LCB4	435	ENKDKNKGCLTFEP...	NPSNPSSPDLLSKNNINNSTKDE.....
Yeast LCB5	478	EH..KNKGSLEFQHITMKNKDNECDN	YENYETENEDEDADADEDSHLIS
S. pombe	308	EKSKNLAPMSESSDSK.....
C. elegans	284TYRPHYKPGFHPSSNVFSVYEKTTQQRIDDSKVKTNGSVSDSEETME	
Consensus	**
hSK	282	AGVMHLFYV..RAGVSRAMLLRLFLAMEKGRHMEYEC	PYLVVYPVVAFRLEPKDGG
mSK1a	280	AGVMHLFYV..RAGVSRALLRLFLAMQKCKHMELD	CPYLHVVPVVAFRLEPRSQ
mSK1b	287	AGVMHLFYV..RAGVSRALLRLFLAMQKCKHMELD	CPYLHVVPVVAFRLEPRSQ
Yeast LCB4	532	DGTIDLVTDARIPVTR..MTPILLSLDKGSH..	VLEPEVIHSKILAYKIIIPKVE
Yeast LCB5	586	DGTMDMVTDARTSLTR..MAPILLGLDKGSH..	VLQPEVLHSKILAYKIIIPKLG
S. pombe	367	DGLIDVVIVYSKQFRKS..LLSMFTQLDNGGF..	YYSKHLNYYKVRSFRTPVNT
C. elegans	388	DNRHLSYILWKDIGTRVNIAYKYLAAIEHETHLDL..	PFVVKHVEVSSMKLEVISE
Consensus		.G.*.*.....*R.*.*L**..G.H.....P.*.*.*.*P...	

Figure 9(ii)

```

FTLMLTERRNHARE.LVRSEELGRWDALVVMSSGDGLMHVEVNVNGLMERPDWETAI.QKPLCSLPAG
FKLILTERKNHARE.LVCAEELGHWDALAVMSSGDGLMHVEVNVNGLMERPDWETAI.QKPLCSLPAG
FKLILTERKNHARE.LVCAEELGHWDALAVMSSGDGLMHVEVNVNGLMERPDWETAI.QKPLCSLPAG
IEIAYTKYARHAID.IAKDLDISKYDTIACASGDGIPYEVINGLYRRPDRVDAFNKLAQTQLPCG
IEVYTKYPGHAIE.IAREMDIDKYDTIACASGDGIPHEVINGLYQRPDQVKAFFNNAITEIPCG
CEVLTTRKDHAKS.IAKNLDVGSYDGILSVGGDGLFHEVINGLYGERDDYLEAF.KLPVCMIPCG
YEVVTTGPNHARNVMTKADLGKFNGLVILSGDGLVFEALNGILCREDAFRIFPTLPIGIVPSG
...T...HA...***D...SGDG*..EV*NGL..R.D...A...***P.G
FVLSLAWGFIADVDLESEKYRR.LGEMRFTLGTFRLRLAALRTYRGRL.....
YVLSLSWGFVADVDLESEKYRR.LGEIRFTVGTFFRLASLRIYQGQL.....
YVLSLSWGFVADVDLESEKYRR.LGEIRFTVGTFFRLASLRIYQGQL.....
LSFLSQTYGVIAESDINTE.FIRWMGCPVRFNLGVAFNI IQKKYPCFVVKYAAKSKKELKVHFL
LSFLSQTYGLIAETDINTE.FIRWMGCPARFELGVAFNI IQKKYPCFVVKYAAKSKNELKNHYL
YSELTANYGIIADCDIGTE.NWRFMGENRAYLGFFLRLFQKPDWKCSIEMDVVSSDRTEIKHMY.
ASFLSIGWGLMADIDIDSEKWRKSLGHHRFTVMGFIRSCNLRSLKGRL.....
.S.LS.**G.*A*.D***E.*.R.*G..RF.*G.....*Y...*

```

Figure 9(iii)

AHLVPLEEPVPSHW.....TVVPD.....EDFVLVLLHSHLGSEMFAAPMGRCA
 THLVPLEEPVPSHW.....TVVPE.....QDFVLVLLHSHLSSSELFAPMGRCE
 THLVPLEEPVPSHW.....TVVPE.....QDFVLVLLHSHLSSSELFAPMGRCE
LSPNFLNEDNFKLYPMTEPVPRDWEKMDSELTDNLTIYTGKMPYIAKDTKFFPAALPA
 RDLADSSADQIKEEDFKIKYPLDEGIPSDWERLDPNISNNLGIFYTGKMPYVAADTKFFPAALPS
TVSTSPESHLLTFEI.NDLSIFCAGLLPYIAPDAKMFPAASND
 TKFQNWTLPDSDETLAVGSSDLEETVVIE.....DNFVNIYAVTLSHIAADGPFAPSAKLE
 ** * * * * * P.....
 KG..MFAVDGELMVSEAVQGQVHPNYFW.MVSGCVEPPPSWKPQQMPPEEPL identity
 RG..VFSVDGELMVCEAVQGQVHPNYLW.MVCGSRDAPSGRDSRRGPPPEP. 81%
 RG..VFSVDGELMVCEAVQGQVHPNYLW.MVCGSRDAPSGRDSRRGPPPEP. 80%
 SG..LFSVDGGEKFPLEPLQVEIMPMLCKTLRNGRYIDTEFESM..... 28%
 NG..LFSVDGGEKFPLEPLQVEIMPRLCKTLRNGRYVDTDFDSM..... 30%
 GKRHYFALDGEISYPLEPFECRVAPKLGTTLSPVAGFQLLDI..... 30%
 GS..HVLVDGEVVDTKTIEVASTKNHIS.VFSSTA..... 30%
 *...F**DGE...E*** * P..... *

Figure 9(iv)

17/21




Figure 10

Substitute Sheet
(Rule 26) RO/AU





Figure 11




Figure 12

20/21




Figure 13




Figure 14

- 1 -

SEQUENCE LISTING

<110> MEDVET SCIENCE PTY LTD

<120> NOVEL THERAPEUTIC MOLECULES AND USES THEREOF

<130> 2293027/TDO

<140>

<141>

<150> PQ0339

<151> 1999-05-13

<150> PQ1504

<151> 1999-07-08

<160> 5

<170> PatentIn Ver. 2.0

<210> 1

<211> 1205

<212> DNA

<213> mammalian

<220>

<221> CDS

<222> (33)..(1184)

<400> 1

```

gaattcggca cgaggagccg cgggtcgagg tt atg gat cca gcg ggc ggc ccc 53
                               Met Asp Pro Ala Gly Gly Pro
                               1                               5

cgg ggc gtg ctc ccg cgg ccc tgc cgc gtg ctg gtg ctg ctg aac ccg 101
Arg Gly Val Leu Pro Arg Pro Cys Arg Val Leu Val Leu Leu Asn Pro
      10                               15                               20

cgc ggc ggc aag ggc aag gcc ttg cag ctc ttc cgg agt cac gtg cag 149
Arg Gly Gly Lys Gly Lys Ala Leu Gln Leu Phe Arg Ser His Val Gln
      25                               30                               35

ccc ctt ttg gct gag gct gaa atc tcc ttc acg ctg atg ctc act gag 197
Pro Leu Leu Ala Glu Ala Glu Ile Ser Phe Thr Leu Met Leu Thr Glu
      40                               45                               50                               55

cgg cgg aac cac gcg cgg gag ctg gtg cgg tgc gag gag ctg ggc cgc 245
Arg Arg Asn His Ala Arg Glu Leu Val Arg Ser Glu Glu Leu Gly Arg
      60                               65                               70

tgg gac gct ctg gtg gtc atg tct gga gac ggg ctg atg cac gag gtg 293
Trp Asp Ala Leu Val Val Met Ser Gly Asp Gly Leu Met His Glu Val

```

- 2 -

75	80	85	
gtg aac ggg ctc atg gag cgg cct gac tgg gag acc gcc atc cag aag			341
Val Asn Gly Leu Met Glu Arg Pro Asp Trp Glu Thr Ala Ile Gln Lys			
90	95	100	
ccc ctg tgt agc ctc cca gca ggc tct ggc aac gcg ctg gca gct tcc			389
Pro Leu Cys Ser Leu Pro Ala Gly Ser Gly Asn Ala Leu Ala Ala Ser			
105	110	115	
ttg aac cat tat gct ggc tat gag cag gtc acc aat gaa gac ctc ctg			437
Leu Asn His Tyr Ala Gly Tyr Glu Gln Val Thr Asn Glu Asp Leu Leu			
120	125	130	135
acc aac tgc acg cta ttg ctg tgc cgc cgg ctg ctg tca ccc atg aac			485
Thr Asn Cys Thr Leu Leu Leu Cys Arg Arg Leu Leu Ser Pro Met Asn			
140	145	150	
ctg ctg tct ctg cac acg gct tgc ggg ctg cgc ctc ttc tct gtg ctc			533
Leu Leu Ser Leu His Thr Ala Ser Gly Leu Arg Leu Phe Ser Val Leu			
155	160	165	
agc ctg gcc tgg ggc ttc att gct gat gtg gac cta gag agt gag aag			581
Ser Leu Ala Trp Gly Phe Ile Ala Asp Val Asp Leu Glu Ser Glu Lys			
170	175	180	
tat cgg cgt ctg ggg gag atg cgc ttc act ctg ggc act ttc ctg cgt			629
Tyr Arg Arg Leu Gly Glu Met Arg Phe Thr Leu Gly Thr Phe Leu Arg			
185	190	195	
ctg gca gcc ttg cgc act tac cgc ggc cga ctg gct tac ctc cct gta			677
Leu Ala Ala Leu Arg Thr Tyr Arg Gly Arg Leu Ala Tyr Leu Pro Val			
200	205	210	215
gga aga gtg ggt tcc aag aca cct gcc tcc ccc gtt gtg gtc cag cag			725
Gly Arg Val Gly Ser Lys Thr Pro Ala Ser Pro Val Val Val Gln Gln			
220	225	230	
ggc ccg gta gat gca cac ctt gtg cca ctg gag gag cca gtg ccc tct			773
Gly Pro Val Asp Ala His Leu Val Pro Leu Glu Glu Pro Val Pro Ser			
235	240	245	
cac tgg aca gtg gtg ccc gac gag gac ttt gtg cta gtc ctg gca ctg			821
His Trp Thr Val Val Pro Asp Glu Asp Phe Val Leu Val Leu Ala Leu			
250	255	260	
ctg cac tcg cac ctg ggc agt gag atg ttt gct gca ccc atg ggc cgc			869
Leu His Ser His Leu Gly Ser Glu Met Phe Ala Ala Pro Met Gly Arg			
265	270	275	
tgt gca gct ggc gtc atg cat ctg ttc tac gtg cgg gcg gga gtg tct			917
Cys Ala Ala Gly Val Met His Leu Phe Tyr Val Arg Ala Gly Val Ser			

- 3 -

280	285	290	295	
cgt gcc atg ctg ctg cgc ctc ttc ctg gcc atg gag aag ggc agg cat				965
Arg Ala Met Leu Leu Arg Leu Phe Leu Ala Met Glu Lys Gly Arg His				
	300	305	310	
atg gag tat gaa tgc ccc tac ttg gta tat gtg ccc gtg gtc gcc ttc				1013
Met Glu Tyr Glu Cys Pro Tyr Leu Val Tyr Val Pro Val Val Ala Phe				
	315	320	325	
cgc ttg gag ccc aag gat ggg aaa ggt atg ttt gca gtg gat ggg gaa				1061
Arg Leu Glu Pro Lys Asp Gly Lys Gly Met Phe Ala Val Asp Gly Glu				
	330	335	340	
ttg atg gtt agc gag gcc gtg cag ggc cag gtg cac cca aac tac ttc				1109
Leu Met Val Ser Glu Ala Val Gln Gly Gln Val His Pro Asn Tyr Phe				
	345	350	355	
tgg atg gtc agc ggt tgc gtg gag ccc ccg ccc agc tgg aag ccc cag				1157
Trp Met Val Ser Gly Cys Val Glu Pro Pro Pro Ser Trp Lys Pro Gln				
	360	365	370	375
cag_atg cca ccg cca gaa gag ccc tta tgatctagag tcgacctgca g				1205
Gln Met Pro Pro Pro Glu Glu Pro Leu				
	380			
<210> 2				
<211> 384				
<212> PRT				
<213> mammalian				
<400> 2				
Met Asp Pro Ala Gly Gly Pro Arg Gly Val Leu Pro Arg Pro Cys Arg				
1	5	10	15	
Val Leu Val Leu Leu Asn Pro Arg Gly Gly Lys Gly Lys Ala Leu Gln				
	20	25	30	
Leu Phe Arg Ser His Val Gln Pro Leu Leu Ala Glu Ala Glu Ile Ser				
	35	40	45	
Phe Thr Leu Met Leu Thr Glu Arg Arg Asn His Ala Arg Glu Leu Val				
	50	55	60	
Arg Ser Glu Glu Leu Gly Arg Trp Asp Ala Leu Val Val Met Ser Gly				
	65	70	75	80
Asp Gly Leu Met His Glu Val Val Asn Gly Leu Met Glu Arg Pro Asp				
	85	90	95	
Trp Glu Thr Ala Ile Gln Lys Pro Leu Cys Ser Leu Pro Ala Gly Ser				

- 4 -

100	105	110
Gly Asn Ala Leu Ala Ala Ser Leu Asn His Tyr Ala Gly Tyr Glu Gln 115 120 125		
Val Thr Asn Glu Asp Leu Leu Thr Asn Cys Thr Leu Leu Leu Cys Arg 130 135 140		
Arg Leu Leu Ser Pro Met Asn Leu Leu Ser Leu His Thr Ala Ser Gly 145 150 155 160		
Leu Arg Leu Phe Ser Val Leu Ser Leu Ala Trp Gly Phe Ile Ala Asp 165 170 175		
Val Asp Leu Glu Ser Glu Lys Tyr Arg Arg Leu Gly Glu Met Arg Phe 180 185 190		
Thr Leu Gly Thr Phe Leu Arg Leu Ala Ala Leu Arg Thr Tyr Arg Gly 195 200 205		
Arg Leu Ala Tyr Leu Pro Val Gly Arg Val Gly Ser Lys Thr Pro Ala 210 215 220		
Ser Pro Val Val Val Gln Gln Gly Pro Val Asp Ala His Leu Val Pro 225 230 235 240		
Leu Glu Glu Pro Val Pro Ser His Trp Thr Val Val Pro Asp Glu Asp 245 250 255		
Phe Val Leu Val Leu Ala Leu Leu His Ser His Leu Gly Ser Glu Met 260 265 270		
Phe Ala Ala Pro Met Gly Arg Cys Ala Ala Gly Val Met His Leu Phe 275 280 285		
Tyr Val Arg Ala Gly Val Ser Arg Ala Met Leu Leu Arg Leu Phe Leu 290 295 300		
Ala Met Glu Lys Gly Arg His Met Glu Tyr Glu Cys Pro Tyr Leu Val 305 310 315 320		
Tyr Val Pro Val Val Ala Phe Arg Leu Glu Pro Lys Asp Gly Lys Gly 325 330 335		
Met Phe Ala Val Asp Gly Glu Leu Met Val Ser Glu Ala Val Gln Gly 340 345 350		
Gln Val His Pro Asn Tyr Phe Trp Met Val Ser Gly Cys Val Glu Pro 355 360 365		
Pro Pro Ser Trp Lys Pro Gln Gln Met Pro Pro Pro Glu Glu Pro Leu 370 375 380		

- 5 -

<210> 3
<211> 24
<212> DNA
<213> mammalian

<400> 3
cggaattccc agtcggccgc ggta

24

<210> 4
<211> 26
<212> DNA
<213> mammalian

<400> 4
tagaattcta ccgcggccga ctggct

26

<210> 5
<211> 52
<212> DNA
<213> mammalian

<400> 5
tagaattcac ttgtcatcgt cgtccttgta gtctaagggc tcttctggcg gt

52

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU00/00457

A. CLASSIFICATION OF SUBJECT MATTER																						
Int. Cl. ⁷ : C12N 9/12, A61K 38/45, C07K 16/18 16/40																						
According to International Patent Classification (IPC) or to both national classification and IPC																						
B. FIELDS SEARCHED																						
Minimum documentation searched (classification system followed by classification symbols) Derwent World Patents Index (WPIDS), Chemical Abstracts (CA)																						
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Medline																						
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CA MEDLINE WPIDS Keywords : sphingosine kinase, sphinganine kinase, ceramide kinase acylsphingosine kinase, dihydrosphingosine kinase, sequence																						
C. DOCUMENTS CONSIDERED TO BE RELEVANT																						
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																				
P,X	WO 00 05365 (SMITHKLINE BEECHAM PLC) 3 February 2000. See particularly p. 3 line 20 - 39, p. 9 line 24 - p. 10 line 4)	1 - 11, 20																				
P,X	AU, A, 40979/99 (OFFICE OF THE DEAN OF RESEARCH AND GRADUATE EDUCATION) 13 December 1999 (See particularly p. 17 line 18 - p. 22 line 35, p. 37 line 21 - p. 39 line 2, and claims)	1 - 26																				
X	The Journal of Biological Chemistry, Vol. 273, No. 37 pp. 23722-23728 (11 September 1998) Kohama, T. et.al. 'Molecular Cloning and Functional Characterisation of Murine Sphingosine Kinase'. (See particularly abstract and Fig. 1)	1 - 11																				
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C <input checked="" type="checkbox"/> See patent family annex																						
<p>* Special categories of cited documents:</p> <table border="0"> <tr> <td>"A"</td> <td>Document defining the general state of the art which is not considered to be of particular relevance</td> <td>"T"</td> <td>later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>"E"</td> <td>earlier application or patent but published on or after the international filing date</td> <td>"X"</td> <td>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>"L"</td> <td>document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>"Y"</td> <td>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>"O"</td> <td>document referring to an oral disclosure, use, exhibition or other means</td> <td>"&"</td> <td>document member of the same patent family</td> </tr> <tr> <td>"P"</td> <td>document published prior to the international filing date but later than the priority date claimed</td> <td></td> <td></td> </tr> </table>			"A"	Document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	"E"	earlier application or patent but published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	"O"	document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family	"P"	document published prior to the international filing date but later than the priority date claimed		
"A"	Document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																			
"E"	earlier application or patent but published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																			
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																			
"O"	document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family																			
"P"	document published prior to the international filing date but later than the priority date claimed																					
Date of the actual completion of the international search 28 June 2000		Date of mailing of the international search report 12 JUL 2000																				
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustalia.gov.au Facsimile No. (02) 6285 3929		Authorized officer ALISTAIR BESTOW Telephone No : (02) 6283 2450																				

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU00/00457

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	The Journal of Biological Chemistry , Vol.269, No. 23 pp.16512 - 16517 (10 June 1994) Su Y, et. al. 'Sphingosine 1-Phosphate, a Novel Signaling Molecule, Stimulates DNA Binding Activity of AP-1 in Quiescent Swiss 3T3 Fibroblasts', (See particularly p.16513, col. 1 line 7 - 13)	7 - 8
A		1 - 6, 9 - 33
A	The Journal of Biological Chemistry , Vol. 265, No. 31 pp.18803 - 18808 (5 November 1990) Kolesnick, R. N. et. al. 'Characterization of a Ceramide Kinase Activity from Human Leukemia (HL-60) Cells' (see whole document)	1 - 33
A	The Journal of Biological Chemistry , Vol. 273, No. 50 pp.33203 - 33209 (11 December 1998) Hinkovska-Galcheva, V. T. et. al. 'The Formation of Ceramide-1-phosphate during Neutrophil Phagocytosis and Its Role in Liposome Fusion' (see whole document)	1 - 33

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU00/00457**Box I** Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos :
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos : 12 - 14, 17 - 19 and 22 - 26
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically: The range of agents claimed, characterised entirely upon their activity, are of unknown scope, and hence neither the agents themselves, or methods of use involving these agents can be searched.
3. ☐ Claims Nos :
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a)

Box II Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/AU00/00457

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report		Patent Family Member	
AU	40979/99	WO	99/61581

END OF ANNEX